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ABSTRACT 
CONTINUUM DEFORMATION MODEL FOR DRUG-ELUTING STENT (DES) 
MEDICAL DEVICES USING FINITE ELEMENT ANALYSIS (FEA) 
 
by 
 
Solki Lee 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Professor Chang-Soo Kim 
 
The development of coronary stent medical devices was originally considered as a 
major advance in the treatment of obstructive cardiovascular disease. The implantation of 
stent, however, involves clinical adverse effects such as re-narrowing of arterial wall after 
stenting. Drug-eluting stents (DES) have been developed to prevent such adverse effects 
by slowly delivering anti-proliferative and/or anti-inflammatory drugs from coating 
composites of drug-containing polymers. One of the major issues in DES implantation is, 
however, that the coatings comprised of drug and polymer composite phases are often 
fractured or delaminated during the deployment of stent, which can lead to more serious 
clinical complications. In this study, we developed a computational model employing the 
finite element analysis (FEA) technique to predict the stress distributions of various 
components in DES medical devices including coating composites. This work is 
considered as one of the first attempts to address the stress concentrations of DES 
medical devices upon implantation using 2D/3D computational approaches. The 
ABAQUS commercial package (Hibbit Karlsson & Sorences Inc., Pawtucket, RI, USA) 
was used to perform computational analyses for systems with large elastic/plastic 
deformations. Designs of three commercial products (SYNERGY, TAXUS Express, and 
 
 
iii 
 
FLEX stents) available in the market have been modeled in this thesis. The displacement 
control method has been adopted in developing our model for the deployment of DES. 
Throughout the present thesis, the impacts of geometry and material variables such as 
stent strut/coating thicknesses and material contents in composites on the mechanical 
performance of the DES were quantitatively examined. Moreover, to predict the rate of 
in-stent restenosis (ISR), we developed a model to include the physiological 
environments, i.e., arterial wall and atherosclerotic plaque, in the system. From the 
results, it has been monitored that the strut thickness and coating thickness of DES are 
one of the major factors determining the amount of stress concentration on the inner 
surfaces of arterial wall and atherosclerotic plaque. The higher von-Mises stress 
accumulation was observed with thicker strut and coating. The findings indicate that the 
optimizing geometry of stent and coating is a critical variable to manipulate its 
mechanical performance and the rate of ISR. The computation results also demonstrate 
that the stress concentrations in the SYNERGY and FLEX DES are much lower than 
those observed in the TAXUS Express stents. 
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Chapter 1. Introduction 
 
 In this chapter, a brief overview, motivations, and the objective of current 
research is given. In the overview section, we provide an introductory information about 
drug-eluting stents (DES) medical devices and finite-element analysis (FEA). 
 
1. Overview 
1.1 Drug-Eluting Stent (DES) 
 
 Drug-eluting stent (DES) is considered as a pivotal biomedical device to treat 
coronary artery disease (CAD) resulted from the plague accumulated in arteries that may 
deteriorate into atherosclerosis. With growing rate of increase in CAD, many medical 
interventions have been developed and applied for those who undergoing CAD. Coronary 
Artery Bypass Grafting (CABG) has been commonly applied to surgical intervention for 
CAD since 1970s to enhance blood flow to the heart by grafting arteries narrowed by 
blockages called plague with healthy arteries that can freely pump in and out blood [1,2], 
however, this intervention has been proven as high-risk clinical protocol for CAD. To 
avoid such high-risk procedure, Percutaneous Transluminal Coronary Angioplasty 
(PTCA) was introduced and initially performed as supplementary intervention during the 
CABG procedure [1]. Balloon angioplasty is a well-known type of PTCA, which was 
considered as a minimally invasive surgical intervention by inserting a balloon tipped 
catheter into and expanding clogged arteries. However, it had a major risk of sudden 
closure and restenosis caused by intimal hyperplasia, which essentially led the 
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development bare metal stent (BMS) [1].  BMS is a small, tubular, wire-mesh devise that 
is pre-loaded in a collapsed form onto a catheter balloon, threaded to the narrowed 
section of the artery and expanded within the vessel. It is considered that BMS generally 
result in extremely favorable initial clinical results, however re-narrowing of the treated 
artery due to in-stent restenosis (ISR) is commonly observed [3]. 
 ISR occurs when the treated vessel is narrowed again after implementing a stent 
in the vessel. Initially, new tissues consist of healthy cells from the lining of arterial wall 
grows inside the stent, which allows blood to flow well over the treated area without 
clotting. When ISR occurs, scar tissues forming underneath the new lining obstruct the 
blood flow and produce a blockage inside the stent [4]. To deal with this ISR, localized 
drug delivery to the targeted vessel wall was introduced, which is widely known as drug-
eluting stents (DES). DES has in principle the very similar structure of BMS comprised 
of tubular, a wire-mesh device, but DES is coated with anti-proliferative/anti-
inflammatory drugs onto coronary stents to prevent ISR on the operated arteries. There 
have been studies that the use of DES appeared to be significantly less risky than BMS 
with regards to the mortality rates, safety, and efficacy [5,6]. There have been many 
initiatives and developments in applying the type of the anti-proliferative drug agents, the 
design of DES stent platform, and the materials used for DES to reduce complications 
after implantation and increase efficacy. In the early stage of DES, silolimus-eluting 
(Cypher, Johnson & Johnson, 2003) and paclitaxel-eluting (Taxus, Boston Scientific, 
2004) stents contributed to reducing the risk of ISR. However, it has been discovered that 
those stents are likely to result in higher chance of occurring late clinical adverse effects 
such as stent thrombosis [3]. Following that, more advanced DES to improve long-term 
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safely and anti-restenotic efficacy have been suggested such as zotarolimus eluting 
(Endeavor, Medtronic, 2009) and everolimus eluting (Xience V, Abbott, 2008) stents [3]. 
Details of commercialized DES products will be address in Chapter 2. 
 
1.2 Finite element analysis (FEA) 
 Finite element analysis (FEA) is one of the widely used computational tools to 
predict the mechanical behaviors of continuum objects/systems. Typical FEA is 
performed based on  a complicated domain that is subdivided into a finite number of 
smaller regions, called ‘elements’, and differential equations are calculated inside the 
element called ‘integration points’. The calculated value is extrapolated to the vertices of 
each element, called ‘nodes’, which is the intersections of elements. After the equations 
are calculated, the smaller sub-regions are assembled, which formulates the overall 
behavior of the entire domain. FEA can use a complex system of nodes which generate a 
grid called a mesh element. This mesh is programmed to contain the material and 
structural properties that define how the structure will react to certain loading conditions. 
Nodes are assigned at a certain density throughout the material depending on the 
anticipated stress levels of a particular area. Regions which will receive large amounts of 
stress usually have a higher node density than those which experience little or no stress. 
The mesh looks like a spider web in which each node is expanded to the adjacent nodes 
by a mesh element. This web of vectors is what carries the material properties to the 
object, creating many elements [7]. 
 There are generally two types of analysis that are used in industry with respect to 
the dimensional analysis; 2D and 3D modeling. While 2D modeling takes the advantage 
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of simplicity and does not require huge computational resources, it tends to yield less 
accurate results. It is known that 3D modeling, however, generally produces more 
accurate results though it requires more computational resources and time. FEA has been 
served as a reliable tool to estimate a solution to the task of predicting failure due to 
external stresses [7]. A variety of specializations under the umbrella of the mechanical 
engineering discipline (such as aeronautical, biomechanical, and automotive industries) 
commonly use integrated FEA in designing and developing their products. Several 
modern FEA packages include specific components such as thermal, electromagnetic, 
fluid, and structural working environments. In a structural simulation, FEA can guide to 
produce stiffness and strength visualizations and also to minimize weight, materials, and 
costs. FEA allows detailed visualization of where structures bend or twist, and it can 
indicate the distribution of stresses and displacements. FEA software provides a wide 
range of simulation options for controlling the complexity of both modeling and analysis 
of a system. Similarly, the desired level of accuracy required and associated 
computational time requirements can be managed simultaneously to address most 
engineering applications. FEA allows entire designs to be constructed, refined, and 
optimized before the design is manufactured. 
 This powerful design tool has significantly improved both the standard of 
engineering designs and the methodology of the design process in many industrial 
applications. The introduction of FEA has substantially decreased the time to take 
products from concept to the production line. It is primarily through improved initial 
prototype designs using FEA that testing and development have been accelerated [8]. 
Benefits of FEA include increased accuracy, enhanced design and better insight into 
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critical design parameters, virtual prototyping, fewer hardware prototypes, a faster and 
less expensive design cycle, increased productivity, and increased revenue. Considering 
such advantages, throughout the current thesis, advanced FEA computational approach 
has been primarily applied in understanding the mechanical behaviors of DES medical 
devices. 
 
2. Motivations 
 
 As stated in the previous section, in predicting the performance of medical stents, 
FEA has a great potential. When we consider the fact that even a small-scale clinical trial 
using stents on human body can give rise to fatality, the more precise computer 
simulation on designing stents would be preferred to reduce practical errors, which can be 
derived from utilizing FEA on mechanically modeling stents.  
 Even though utilizing DES clearly decreases the possibility of ISR occurrence, it 
still accompanies several critical drawbacks. One of the major issues in DES implantation 
is that the coatings comprised of drug and polymer phases are often fractured or 
delaminated during the deployment of stent. Upon expansion, localized regions of high 
plastic strain, such as hinge or intersection of stent struts, experience complicated 
mechanical deformation that leads to the fracture of the coating (see Fig. 1.1). It is 
important that the coating maintain its mechanical integration and adhesion to the stent 
platform because the fracture of coating could affect the delivery of the drug and it can 
cause a more serious problem such as stroke. Further, stent coating failure after 
implantation could lead to various clinical problems, such as restenosis and thrombosis. 
The amount of drug dosage, in addition, could possibly change or the delivery misguided 
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by such coating delamination and/or fragmentation. Even toxic or irritant ions from the 
metallic stent strut can be released if there is a breakdown of the coating barrier, 
precipitating the inflammatory response [9]. There is a very large plastic deformation 
during the stent expansion, and the coated polymer layer could be delaminated from the 
metal platform. If the polymer layer is separated from the stent strut, the debris or particle 
could drift along blood which can reach anywhere in humans’ body. This could cause 
serious problem such as stroke. Though it is known that the coating 
delamination/fragmentation is an important issue in DES implantation, not many 
computational modeling work has been reported. C. G. Hopkins et al [10] have developed 
a FEA model of coating delamination of DES in 2010. In this study, a cohesive zone 
model of the stent-coating interface is implemented to investigate coating de-bonding 
during stent deployment. This study provided insight into the critical factors governing 
coating delamination and offers a predictive framework that can be used to improve the 
design of coated stents. However, there is a limitation that this work has only 2D 
perspective and the consideration of the presence of artery and plaque was not taken into 
account. Fig. 1.2 shows the FEA of coating delamination phenomena. 
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Fig. 1.1 Delamination of stents coatings after stent deployment (a) stent hinge region (b) 
Cypher stent (Adopted from C. G. Hopkins et al [10]). 
 
 
Fig. 1.2 (a) Real stent coating delamination. (b) FEA model of coating delamination [10]. 
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3. Objectives of Research 
 
 In this study, a computational model is developed to predict the stress 
distributions of various components in DES medical devices. Especially, our objective of 
this thesis is that: 
 
 FEA computational model development including the coating components in the 
system to understand the mechanical responses in the drug-polymer coating upon 
DES deployment.  
 
 Though our focus is on the coating fracture of DES, in the present work, we 
developed our model to include comprehensive components of the DES + arterial wall 
system including stent platform, coating, plaque, and arterial walls, to investigate other 
phenomena such as recoiling and stress distributions in the arterial walls. In developing 
the model, the necessary elastic and plastic physical properties of constituent materials 
such as metallic platform, polymer, atherosclerotic plaque, and arterial wall are 
incorporated. In the following chapters (Chapters 2, 3, and 4), the detailed background, 
previous modeling efforts, and our model development are addressed, respectively. In the 
result chapter (Chapter 5), the impacts of geometry and material variables such as coating 
thickness and material contents in composites on the mechanical performance of the 
medical device will be discussed. 
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Chapter 2. Drug-Eluting Stents (DES) 
 
 Cardiovascular stenting has made a remarkable improvement in the field of 
coronary disease management during the last several decades. Bare-metal stents (BMSs) 
were introduced in 1994, but the long-term results have been shattered by the adverse 
problems including in-stent restenosis (ISR) and stent thrombosis associated with BMSs. 
Although stent thrombosis became much less frequent after the introduction of 
antiplatelet therapy, the occurrence of ISR, however, remained as a significant problem. 
The intense work on stent development has successfully led to the introduction of drug-
eluting stents (DES) in 2002, as an effort to address this ISR problem. In this chapter, we 
provide the basic information of DES and its drug components. In addition, the general 
development trends of DES will be covered at the later part of this chapter. 
 
1. Components of Drug-eluting Stents (DES) 
 
 DES is composed of three main components; stent platform, polymer, and drug. 
The platform functions as a scaffold to keep a diseased artery open, and the polymer 
carries the drug while the drug is directly delivered into the injured site. The polymers 
and drugs typically form a thin composite coating on the platform surface. 
 
1.1 Platform 
 Available platforms in DES applications are generally made of stainless steel, 
cobalt-chromium, or platinum-chromium alloys. The platforms made with a thinner strut 
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may result in less arterial injury and reduce the risk of restenosis, with lower 
thrombogenicity. Platinum-chromium alloys are used in an effort to improve radial 
strength and conformability of DES [1].  
 
1.1.1 Platform Geometry (Design) 
 The type of stents is in general categorized into two groups, self-expanding and 
balloon-expandable stents. In self-expanding design, stents can be constructed from coil, 
mesh, or zig-zag configuration, of which an outer sheath forces the stents to elastically 
spring open into a predetermined size. The balloon-expandable stents are supplied in the 
crimped form, pre-mounted on a balloon, inflation of which plastically deforms the stent 
to the size of the inflated balloon [2]. In addition, the balloon-expandable stents may be 
divided into coil and tube designs. The coils may be fashioned from a continuously 
wound wire or a series of flat sheet coils. The tube stents are cut from a steel tube or, 
occasionally, from a flat sheet of metal, which is then rolled into a tube and welded. For 
the coil stents, the strut width is generally greater than that of the tubular stents, but so are 
the gaps between the struts, and there are fewer or no connections between the struts [3]. 
Due to these geometrical characteristics, the coil stents exhibits more flexibility, but they 
have a poor radial strength and they allow tissue prolapse between the widely-spaced 
wire elements. The differences between these coil and tube stents are schematically 
described in Fig. 2.1. 
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Fig. 2.1 Example of coil (top) vs tube (bottom) designs of stents. (Adopted from A. C. 
Morton et al. 2004 [4]) 
 
 Moreover, the tubular balloon-expandable stents may be divided into ‘slotted 
tube’ and ‘modular tube’ designs. Both are laser-cut from a tube of metal, although some 
modular designs are composed of rings of wires that are welded together. The distinction 
between ‘slotted tube’ and ‘modular tube’ is less clear in modern stent designs because 
the tubes can be cut with few links and ‘open cell’ designs to produce a quasi-modular 
structure. The slotted tube stents with ‘closed cell’ designs, such as the NIR 
(Medinol/Boston Scientific) and Bx Velocity (Cordis/Johnson and Johnson) are close to 
the original concept of a slotted tube. On the other hand, the ‘open cell’ designs, such as 
the Multilink Penta (Guidant), are more like a modular stent. Fig. 2.2 illustrates examples 
of closed- and open-cell designs of stents. The slotted tubes, in particular, with a closed 
cell design, are inherently less flexible than a modular design, but much ingenuity has 
been exercised in designing articulations for the slotted stents with either closed- or open 
cell design to provide reasonable flexibility. It seems that both stents have retained their 
popularity in the latest generation of stents [5]. Recently, the number of curves on a ring 
for DES has been increased as it could increase the stent radial force and the potential 
surface area for DES and it may decrease neointimal proliferation. In the meantime, a 
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thickness of strut is decreasing as it can decrease the inside injury of vessel after 
implementing. However, reducing the thickness of a strut has certainly limitations due to 
the strut fatigue and variation with the types of metal used.  
 
 
Fig. 2.2 Examples of a closed-cell design stent (top) and an open-cell design stent 
(bottom). The black shaded areas represent free cell area of stents. 
 
1.1.2 Platform Material 
 There are many required properties for relevant materials used in stent platform. It 
is critical to obtain not only the biocompatibility or biostability for the platform material, 
but also the balance between radial strength and deformability for the thicknesses 
required for stent manufacture, without a tendency to corrode. For the last 15 years, the 
standard material applied to balloon-expandable stents was 316L stainless steel that 
meets the criteria mentioned above. However, visualizing the small stainless steel devices 
under X-ray fluoroscopy was a challenge. It this early stage, flexibility was listed as one 
of the principal requirements of a stent, so as to easily track through the guide catheter 
and through the tortuous anatomy of the coronary arteries. Improved flexibility may be 
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achieved by reducing stent strut thickness when the strength of the material allows for 
such reductions. Thinner struts result in even less X-ray attenuation, further reducing 
device visibility during deployment. These conflicting requirements of reducing strut 
thickness, while maintaining or improving device radiopacity, were initially addressed by 
the addition of highly radiopaque materials such as tantalum, platinum, or gold, in 
manufacturing coatings or marker bands.  
 Coatings on a stent strut appeared to offer the ideal solution, allowing radiopacity 
to be tuned in proportion to coating thickness. Gold (Au), one of the most inert metals, 
has been studied as a potentially neutral stent coating. However, surprisingly, it has been 
reported that Au is associated with increased rates of ISR and thrombosis [6]. Likewise, 
the properties of stainless steel stents interfaced with other metals can be influenced by 
the surface metals in terms of the possibility of ISR and/or thrombosis. As the main 
constituent of stents, the supremacy of stainless steel (i.e., 316L) is now being challenged 
by the advanced alloys of cobalt, chromium and platinum. These metals with a thinner 
strut can provide a similar mechanical property to stainless steel. The ISAR-STEREO 
trial demonstrated the advantage of thinner struts for patient outcomes, that is, thinner 
struts resulted in lower restenosis rates compared to thicker struts [7]. It was hypothesized 
that thinner struts resulted in lower vascular injury and therefore less subsequent 
neointimal growth. With the thinner struts now being linked to both improved procedural 
and clinical outcomes, the development of the stent material became focused on higher 
strength alloy as it was becoming evident that the moderate yield strength of 316L 
stainless steel would become a limiting factor. Specifically, it would not be possible to 
maintain stent compression strength in 316L devices with thinner flexible struts. In 
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addition, thin-walled 316L devices will lead to undesirably low radiopacity. The effort to 
find the alloys with a higher strength with improved X-ray attenuation compared to 316L, 
initially resulted in the selection of the commercially available cobalt-chromium based 
alloys such as L605 (Co-20Cr-15W-10Ni)  and MP35N® (Co-20Cr-35Ni-10Mo). Sketch 
et al. [8] reported on the first clinical usage of a L605 stent in 2003, demonstrating the 
benefits of the reduced strut thickness achievable with this material. It was subsequently 
followed by a study comparing devices made from MP35N® against these L605 stents, 
which showed the comparable long-term performance of both devices [9]. The 
introduction of these higher strength materials had facilitated the development a new 
generation of stents with the thinner strut thicknesses in the range of 80-90 µm, compared 
to the strut thicknesses of 130-140 µm for the earlier 316L devices. While these Co-Cr 
materials possess higher radiopacity than 316L, the diminution of the strut thickness from 
316L to Co-Cr materials was relatively moderate. It can be proven by the comparison of 
the density values; 9.1 g/cm3 and 8.4 g/cm3 for L605 and MP35N®, respectively, and 8.0 
g/cm3 for 316L [10]. In searching for further improvements in radiopacity with a high 
strength, a new alloy was tailored specifically, for stent applications in mind. These 
alloys are typically based on stainless steel, but in many cases, platinum is substantially 
added to enhance both the mechanical (i.e., tensile) properties and radiopacity [11]. 
 Other than metallic materials, polymeric materials also have been applied to the 
stent platform. The first generation of polymer stents, using materials such as polyester 
(PE), revealed some promises on its mechanical properties [12]. Unfortunately, however, 
most of these polymers elicited a marked local inflammatory response with excessive 
neointimal formation [13]. There has been a recent revival of the interest in 
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biodegradable polymer stents. A study of the physical properties of a poly-L-lactic acid 
(PLA) stent showed some favorable results in inclusion of a collapse pressure of >2 atm; 
a value similar to that of a metal Multilink Tetra stent (Guidant; slotted tube) [14]. If the 
stent platform material is made of non-radiopaque such as biodegradable polymer, it 
needs to have radiopaque markers at the proximal and distal ends of the stent. The 
corrosion phenomenon is, in addition, another important factor, and therefore, it is 
considered as essential to select a material that would develop a passive oxide layer to 
avoid the corrosion. 
 
1.2 Polymer Coatings: Drug Delivery Vehicle 
 In general, it is known that percutaneous transluminal coronary angioplasty 
(PTCA) cannot be operated without damaging blood vessels and eliciting restenosis. 
Drug elution at the target site is a clear solution to this problem. As a result, most of 
currently approved DES consist of a metallic scaffold surrounded by polymer matrix 
containing drug. Polymer coatings are required for most drugs because they do not easily 
adhere to the metallic stent surface. The polymer coating also modifies and controls drug 
elution kinetics, which can be varied by using multiple polymer layers to achieve optimal 
drug release over time. These polymers bind the drug to the stent and modulate the 
elution of the drug to the arterial tissue. Polymer has advantageous characteristics as drug 
delivery vehicle for DES such as biocompatibility, metabolization in the body, minimal 
drug release into the circulation, no alteration of incorporated drug activity and structural 
and operational stent characteristics, competitive adhesion to the stent material of choice, 
and surface finish, and etc. 
18 
 
 
 
 The aforementioned characteristics of polymer may be closely aligned with the 
required features of drug delivery vehicle for DES applications. Taking advantage of 
these beneficial properties, the polymeric materials have been widely used as drug 
delivery vehicles in DES. There are two types of drug delivery vehicles; i) non-
absorbable biostable polymer coating and ii) biodegradable polymer coating. The non-
absorbable biostable polymer coating is a technically simpler design, which leads to 
easier handling and applying onto the struts. However, in the non-absorbable biostable 
polymer coating, the coated drug is passively diffused to the treated vessel, which can 
lead to the necessity of manipulating the diffusion rate of the drug by controlling the 
polymer architecture and/or porosity of the top coat. The biodegradable polymer coating 
method, on the other hand, improves dosing consistency and is able to support a 
customized diffusion pattern of the drug. Also, the multi-drugs can be coated and 
delivered simultaneously and sequentially. With the biodegradable polymer coating, the 
coated drug is diffused via the surface and/or bulk erosion, and the composition of the 
polymer is intentionally controlled to manipulate the delivery rate of the drug. 
 In recent years, the biodegradable polymer coating has received much more 
attention as drug delivery vehicle to improve the performance of DES. It comes from the 
characteristic that biodegradable polymers can be hydrolyzed with ease into metabolized 
molecular weight degradation products in a body. This characteristic also, leads to the 
fact that a biodegradable delivery system does not have to be removed after completion 
of drug release. In vitro studies showed that biodegradable polymers were highly 
biocompatible in a porcine coronary artery model and the histopathological evaluation 
showed only a mild inflammatory response. The extent of ISR in a single polymer 
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coating stent was comparable with that of bare metal stents. More seriously, the clinical 
adverse effects including ISR and thrombosis are often observed from the patients 
implanted with non-degradable polymer DESs. However, unfortunately, some adverse 
reactions may be caused by both of these polymers. It has been reported that, in an early 
stage of the polymeric DES implantation, both biodegradable and non-biodegradable 
polymers could cause a deteriorated inflammatory reaction and neo-intimal proliferation 
[14]. In this next sub-sections, the general requirements, types, and the current trend of 
using polymers as a drug carrier in DES system will be discussed. 
 
1.2.1 Requirements for a polymer used in a DES 
 For the successful commercial DES products, the materials chosen to deliver the 
drug from the stent must meet several key requirements, including physical properties, 
stability (processing, aging, and sterilization), non-reactivity with the incorporated drug, 
process compatibility, biocompatibility with vascular tissue, and the ability to control the 
elution of drug from the stent. In Fig. 2.3, the illustration is presented to address the 
important factors for the polymers used in DES applications.  
 
Fig. 2.3 Required polymer properties in DES medical device applications (schematics 
adopted from T. Parker et al. 2010 [14]) 
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1.2.1.1 Physical properties 
 First of all, the polymer must not adhere to the deployed balloon at storage and 
processing temperatures. In the meantime, the polymer must accommodate stent 
deformation during deployment without cracking or peeling, and must adhere strongly to 
the stent surface, generally stainless steel or Pt-Cr alloy, or to a primer layer such as 
poly(butyl methacrylate) (PBMA). 
 
1.2.1.2 Stability 
 The polymer coating must remain stable during processing, storage and use 
(coating, crimping, sterilization, packaging, shelf storage and stent deployment). Stability 
infers no change in chemical composition (e.g., oxidation), physical integrity of the 
coating, or distribution of drug in the coating. For most DES, solvents are used to apply 
the polymer-drug mixture to the stent. For the chemical stability with the polymer and 
stent, the type of solvents must be carefully considered. Since DESs are sterilized in the 
later stage of manufacturing, the polymer matrix must be stable to ethylene oxide, 
electron beam, or gamma irradiation [14]. Often the choice of polymer will be dictated by 
the desired mode of sterilization and the potential for polymer reactivity or degradation.  
 
1.2.1.3 Compatibility with the drug 
 The polymer needs to remain physically and chemically compatible with the 
incorporated drug. Physical compatibility requires the invariability of the drug-polymer 
morphology after manufacturing in any way that may adversely affect the drug release 
profile. Chemical compatibility requires a lack of chemical reactivity between polymer 
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and drug during processing or shelf storage. Generally, this is not a problem for 
hydrocarbon- or fluorocarbon-based matrices due to the stability of C-H and C-F bonds, 
but polymers may contain the functional groups (such as esters, amides, anhydrides, etc.) 
that could react with the drug [14]. Consequently, the drugs that contain a reactive 
functional group need to be evaluated for the long-term chemical stability to ensure that 
no polymer-drug adducts are formed.  
 
1.2.1.4 Biocompatibility with vascular tissue 
 When DESs are implanted in arteries, the polymers are in direct contact with the 
vessel wall. Therefore, it is critical to maintain good biocompatibility in a long-term 
period. Vascular compatibility of the polymer must be extensively evaluated using in 
vitro and in vivo test methods. Animal safety testing will determine the potential of the 
polymer coating to inhibit re-endothelialization, induce inflammation and produce vessel 
injury or necrosis over a period of one to six months or longer. The extrapolation of 
animal data to human safety must be carefully conducted because certain species may be 
more prone to inflammation after the implantation of foreign materials than other species. 
The demonstration of long-term safety in humans may require years to ascertain. 
 While a biostable polymer has its limitation on the permanent fixity onto the 
implanted DES, a bioabsorbable polymer arouses the necessity of considering the 
degradation products and degradation time. In evaluating the biocompatibility of 
bioabsorbable polymer systems, it is important to test the final drug/polymer formulation 
in preclinical models for the entire resorption period of the polymer. 
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1.2.1.5 Control of drug elution 
 Drug release is controlled by the physiochemical properties of the specific drug 
and the polymer, particularly the morphology of the drug-polymer mixture. To be 
effective, the polymer matrix must control the elution of the drug and provide the desired 
concentration and release profile to produce the maximal therapeutic benefit. Generally, 
it has been determined through clinical experiences that a rapid burst release of a drug 
from a DES is far less effective when compared to sustained release. For instance, it has 
been found that, for paclitaxel used to treat restenosis, a sustained release of at least 30 
days can safely and effectively attenuate neointimal hyperplasia and minimize restenosis 
[14]. 
 
1.2.2 Types of polymers 
1.2.2.1 Non-biodegradable polymers 
 In the area of non-absorbable, biostable, permanent polymers, a variety of 
chemical classes have been used as a drug carrier for a local delivery [15, 16]. Although a 
particular polymer may be tolerated in another location of the body, for DES application, 
the polymer material must be hemocompatible, non-thrombogenic, and non-
inflammatory. A limited number of biocompatible polymers are commercially used in 
DES products (available in the US) as shown in Table 2.1. 
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Stent Company Polymer Matrix 
Composition 
Year 
Cypher Cordis  PEVAa+ PBMAb 2003 
Taxus® / Taxus Liberte® 
 
Boston 
Scientific 
SIBSc 2004 
Xience V Abbot 
Vascular 
PVDF-HFPd 2008 
Promus Boston 
Scientific 
PVDF-HFP 2009 
Endeavor Medtronic Methacrylated 
phosphorylcholine- 
based (PC (cross-linked)) 
2009 
Table 2.1 Permanent polymers used as the drug delivery matrix for DES products 
approved in the US [12]. In the Table, the symbols represent as, a: Poly(ethylene-co-vinyl 
acetate); b: Poly(n-butyl methacrylate); c: Poly(styrene-block-isobutylene-block-styrene); 
d: Poly (vinylidene fluoride-co-hexafluoropropylene) 
 
1.2.2.2 Biodegradable polymers 
 One of the potential advantages of biodegradable polymers comes from the fact 
that they provide a matrix to release a drug, and then, fully degrade over time. It can, 
therefore, eliminate the concerns about vascular biocompatibility in a long term period. 
The selection of a biodegradable polymer for a drug-eluting device is based on the 
degradation mechanism, degradation time, time-dependent physical properties, and 
processing conditions (drug-polymer interaction and stability). There is a myriad of the 
factors that will affect the degradation of the polymers including chemical composition, 
distribution of repeat units, presence of ionic groups, presence of chain defects, molecular 
weight and molecular weight distribution, morphology (amorphous/semi-crystalline; 
microstructure, etc), presence of low molecular weight compounds, processing 
conditions, annealing, shape and surface area, sterilization process, storage history, 
implantation site, and mechanism of hydrolysis [17]. 
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 Biodegradable polymers can fall into bulk-erodible and/or surface-erodible 
materials in terms of degradation mechanism [18]. Theoretical models have been 
developed to predict the erosion mechanism of water insoluble bioabsorbable materials 
[19,20]. Surface erosion polymers are typically hydrophobic with water labile linkages. 
Hydrolysis tends to occur quickly on the surface of surface erodible polymers with no 
water penetration in bulk. A summary of the different polymer systems for a controlled 
drug release has been provided in the review article [21]. The typical examples of 
surface-erodible polymers include polyanhydrides [22-24] such as poly(carboxyphenoxy 
hexane-sebacic acid), poly(fumaric acidsebacic acid), poly(carboxyphenoxy hexane-
sebacic acid), poly (imide-sebacic acid), and poly(imide-carboxyphenoxy hexane), and 
polyorthoesters (POE) [25]. Bulk-erodible polymers, on the other hand, are typically 
hydrophilic with water labile linkages. Hydrolysis of bulk-erodible polymers tends to 
occur more uniformly across the polymer matrix of the device. The examples of bulk-
erodible polymers include poly(α-hydroxy esters) such as poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), and poly(lactic acid-co-glycolic acid) (PLGA), and also 
poly(caprolactone) (PCL), poly(pdioxanone) (PDO), poly(trimethylene carbonate) 
(PTMC), poly(oxaesters), poly(oxaamides), and their co-polymers and blends [26]. The 
most widely used bioabsorbable polymers for drug eluting stents are from the poly(α-
hydroxy ester) family of materials that include poly(lactic acid) (L-PLA and DL-PLA) 
and their copolymers (PLGA).  
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Stent Company Polymer/Drug Matrix Composition 
BiomatrixTM Biosensors DL-PLA/Biolimus A9 
EpitomeTM Elixir Polyester/Myolimus 
GenousTM OrbusNeich SynBiosysTM/Sirolimus/anti-CD-34 
InfinniumTM Sahajanand DL-PLA/Paclitaxel 
JACTAXTM Labcoat DL-PLA/Paclitaxel 
NEVOTM Cordis DL-PLGA/Sirolimus 
NoboriTM Terumo DL-PLA/Biolimus A9 
SparrowTM CardioMind SynBiosysTM/Sirolimus 
SupralimusTM Sahajanand DL-PLGA/Sirolimus 
Table 2.2 Biodegradable Polymer Coatings for DES [27]. 
 
 Recently, a number of drug eluting stents has been developed using bioabsorbable 
polymers [28,29], which is summarized in Table 2.2. PLGA is a widely investigated 
biodegradable polymer that has been used in a variety of the approved biomedical 
applications, including absorbable sutures, orthopedic devices and controlled drug 
delivery implants [30-33]. PLGA consists of a broad family of the polymers with varying 
ratios of lactide and glycolide monomer and a range of molecular weights. The ratio of 
lactide of glycolide co-monomer units determines the rate of PLGA hydrolysis and 
degradation, as well as the drug elution profile. It has been found that bioresorption time 
is fastest for the 50/50 mole ratio copolymer, and slows as the proportion of lactide is 
increased [34,35]. Additionally, the drug type can affect the degradation rate of PLGA 
matrices [36], as can irradiative sterilization [37]. In vivo, PLGA is degraded by random 
hydrolytic scission of the ester linkages to oligomers of successively lower molecular 
weight. The ultimate fate of PLGA in the body is the degradation to lactic acid and 
glycolic acid residues that are subsequently fully metabolized via the Krebs cycle to 
carbon dioxide and water [38,39]. 
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1.3 Drugs 
 In DESs, the drug melded in the polymer is a biologically active agent to inhibit 
arterial neointimal hyperplasia by suppressing platelet activation, inflammatory response, 
smooth muscle cell migration, and proliferation in an artery. Ideally, the drug should have 
an outstanding overall safety profile and a broad therapeutic window. Besides the 
biological effects, the drug has its own chemical properties that influence achieving 
optimal tissue concentrations and the possibilities for loading on a stent. Some drugs can 
be loaded directly onto the metallic surface of the stent, but most drugs need a polymer 
coating, which forms a reservoir for them. 
 Local delivery of a drug using a DES provides both biological and mechanical 
solution and has emerged as a very promising approach effective in management of ISR. 
For the local drug delivery to be successful, the challenges to be addressed include the (i) 
decision on the most appropriate agent to be use, (ii) determination of the proportion of 
the systemic dose needed locally, and (iii) identification of a biocompatible vehicle that 
can deliver drug for the required therapeutic window [40,41]. Four classes of the drugs 
(anti-inflammatory, anti-thrombogenic, anti-proliferative, and immunosuppressive) are 
generally considered as a candidate to be used in DES. These drugs inhibit one or more 
biochemical pathways leading to restenosis. Some studies have been also, conducted 
using antibodies blocking specific receptors as active compounds [42]. Several reports 
have been published evaluating these drugs regarding their release kinetics, effective 
dosage, safety in clinical practice, and benefits [42-44]. In the next sub-sections, some 
information about the commonly used drugs in DES applications will be provided. 
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1.3.1 Paclitaxel 
 Paclitaxel, a lipophilic molecule derived from the Pacific yew tree Taxus 
brevifolia, is a very common component of chemotherapy for cancer treatment. The 
vascular compatibility and efficacy of paclitaxel in reducing neointimal hyperplasia after 
balloon and stent mediated injury have been shown both in vitro and in vivo [43]. The 
mode of action is the polymerization of the α- and β- units of tubulin, thereby stabilizing 
microtubules that are needed for G2 transition into M-phase. Paclitaxel is also able to 
inhibit the proliferation and the migration of smooth muscle cells because of the 
structural changes in the cytoskeleton, one of the major steps in the development of 
atherosclerosis and restenosis [44,45]. 
 
1.3.2 Sirolimus/rapamycin 
 Till date, the six drugs of the limus family have been studied including sirolimus, 
zotarolimus, everolimus, biolimus A9, tacrolimus, and pimecrolimus [46]. Sirolimus, also 
called rapamycin, is a macrocyclic antibiotic with the potent immunosuppressive 
properties. It acts as a pro-drug that binds to specific cytosolic proteins (FK-506 binding 
protein-12), which blocks the cell proliferation. Rapamycin also inhibits several phases of 
the restenosis cascade, such as inflammation, neointimal hyperplasia formation, total 
protein and collagen synthesis, and migration of smooth muscle cells. Sirolimus is also a 
strong inhibitor of inflammation without cellular toxicity in a low dose [44,45,47]. 
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1.3.3 Zotarolimus and everolimus 
 Zotarolimus and everolimus are analogues of rapamycin. Both have a similar 
action mechanism for the prevention of restenosis. They bind to cytosolic FK-506 
binding protein-12 and inhibit the proliferation of smooth muscle cells and T-cells. The 
compound with them has also higher noctanol/water partition coefficients than rapamycin 
that favors a slow release from the stents. Despite the structural changes, the biological 
activity of rapamycin was retained. The slow rate of release and subsequent diffusion of 
the molecule facilitates the maintenance of the therapeutic drug level from the stent. In 
addition, its lipophilic character favors crossing cell membranes to inhibit neointimal 
proliferation of the targeted tissue [1,22,40]. 
 
2. Current Commercial DES Products 
2.1 General trend of DES development 
 The development of DES in the industry can be categorized into three stages in a 
time order; first, second, and third generation of DES. The potential of the first 
generation stents to cause thrombosis due to a permanent polymer has led to extensive 
researches in developing the new polymers. These efforts have led to the second 
generation of DESs that have more biocompatible non-erodible polymers, which have 
been shown in the animal studies to have a greater degrees of re-endothelialization 
compared to the first generation stents [48]. The researches afterward have also led to the 
design of the third generation DESs that have a biodegradable polymer or novel coating, 
or are completely polymer-free. Table 2.3 shows the summary of the specific names of 
the products and types of the drugs that have been applied, and Fig. 2.4 shows the images 
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of the various commercial DESs. The general trend nowadays, prefers a thinner strut than 
the thicker since it reduces the induced stress on an artery wall and plaque so that the rate 
of restenosis and thrombosis could be decreased. In general, the mechanical properties of 
a stent material are weakened if the thickness of the strut becomes thinner. Therefore, the 
alternative materials, such as Pt-Cr alloy, are developed so as to replace the conventional 
metals such as 316L stainless steel. As mentioned above, the tensile properties and 
density of this Pt-enhanced alloy compare favorably, with stainless steel and Co-Cr 
alloys. It enables the stent designs to have both thinner strut and higher radiopacity. The 
design used for the stent platform also changed from the slotted tube-like to the crown-
shaped to obtain more blood flow.  
 
 First generation Second generation Third generation 
Drug used Sirolimus, Paclitaxel Zotarolimus, 
Everolimus 
Biolimus, 
Everolimus 
Material/design Stainless steel/ slotted Co-Cr/ thin struts Pt-Cr, Ni-Ti, etc 
used for platform Tube design stents  
Polymers used Durable Persistent Biodegradable 
polymer coated 
DES, 
   Polymer free & 
Biodegradable DES 
Commercial products Cypher, TAXUS Endeavor, Xience V SYNERGY, 
Biomatrix Flex 
Table 2.3 The generations of DES [revised from Khan (2012, pp.704)] [27] 
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Fig. 2.4 Several types of commercial DES [49]. 
 
2.2 Future stents 
 Although the first-generation DESs achieved higher efficacy in reducing the 
occurrence rate of ISR, the long-term safety issue has arisen, learning these devices stand 
in a delicate balance of the occasionally conflicting key properties of deliverability, 
efficacy and, safety. As part of an effort to resolve these issues, there are various trends 
leading to various improved DES platforms; e.g., DESs with more biocompatible stent 
coatings, new metallic platforms, new drug combinations, biodegradable polymers, and 
polymer-free and/or fully-biodegradable DESs. Most of these devices are under 
investigation in clinical trials, and recently, some of them have become commercially 
available for the clinical use. Although the best DES has yet to be identified, it will 
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probably, incorporate many of the modern materials and delivery systems described 
earlier to enhance the safety, efficacy and cost-effectiveness. The ideal DESs should be 
composed of the backbone that provides adequate radial strength, deliverability, and 
radiopacity with a minimal vessel wall injury. The drug vehicle should have an ideal drug 
release that does not result in inflammatory response, and the drug or the drug 
combination should inhibit smooth muscle cell proliferation and inflammation effectively 
without delaying re-endothelialization or causing endothelial dysfunction. By combining 
the new drug carriers and structural design improvements with a modern mechanical and 
manufacturing approach, the development of an ideal DES appears to proceed in an 
iterative fashion; with slow but continuous improvements for this revolutionary class of 
the medical device.  
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Chapter 3. Previous Models 
 
This chapter contains a review of previous FEA models for DES applications. 
Numerous models and theories using FEA have been proposed to address various aspects 
(i.e., mechanical and pharmaceutical) of DES implantation. Here in our review, only 
some important previous studies are introduced. For convenience, we have categorized 
the previous models into two groups; models without and with arterial wall systems. At 
the end of the Chapter, a brief summary on the prior FEA modeling efforts is also 
provided.  
 
 
1. Models without Arterial Wall System 
FEA models that do not include arterial wall system are relatively simpler than 
the models with cardiovascular environment systems. Due to the limitation of 
computational resources, the maximum number of elements in the system must be 
considered during the analysis. In this sense, the models without arterial wall system have 
an advantage in evaluating the performance of stent platform itself since much more 
number of elements can be applied to it.  
 
1.1 C. Dumoulin and B. Cochelin, 2000 [1]  
Dumoulin and Cochelin [1] have opened the area of study of FEA application for 
stent in 2000. The objective of their study was to evaluate the long-term performance and 
the deployment characteristics of a Palmaz-Schatz stent (Johnson & Johnson, New 
Brunswick, NJ, USA) during free expansion. The simplest of the numerical models 
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considered in this study was based on the repeating unit cell of the Palmaz-Schatz stent  
and applied internal pressure load on its inner surface so as to achieve expansion. This 
stent product appears like a little slotted metallic tube with diamond-shaped cells after 
expansion (Fig. 3.1). The decision to consider only the repeating unit cell of the stent was 
justified after the investigators examined the in vitro expansion of a Palmaz-Schatz stent, 
concluding that it was almost uniformly expanded and evenly dilated, except at its distal 
ends. They calculated and compared the results of radial and longitudinal recoil rates with 
the manufacturer’s data. Additional numerical models were then proposed to evaluate the 
buckling and fatigue life of the Palmaz-Schatz stent.  
 This study is meaningful because it is considered as the first attempt to apply FEA 
for stent medical devices to predict their mechanical performance. The  
comparison of radial and longitudinal recoil rates between computation and 
manufacturer’s experimental data was successfully conducted. However, the 
developed model in this study only has the stent strut without the existences of 
artery, plaque, and coating components. In addition, the evaluation of stresses on 
stent strut is not included as well. Still, the numerical results reported in this study 
are widely cited in many literatures to demonstrate that stent-free expansion may 
be accurately simulated using FEA. 
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Fig. 3.1 Initial and expanded configuration of the stent with expanded range size; with 
expansion, the staggered slots in the wall assume a diamond shape (Figure adopted from 
C. Dumoulin et al., 2000 [1]). 
 
1.2 Migliavacca et al., 2002 [2] 
The model presented by Migliavacca et al. [2] has an investigation of the effect of 
geometrical parameters such as metal-to-artery ratio, strut thickness and cell length on the 
deployment characteristics of a Palmaz-Schatz stent. In addition, this study has a 
comparison with the performance of Palmaz-Schatz stent and two other next generation 
stents: the Carbostent (Sorin Biomedica, Saluggia, Italy) and Multi-Link Tetra (Guidant, 
Indianapolis, IN, USA) stents. All of the stent models are expanded by pressure control, 
which is carried out by applying pressure load on the inner surface of stent strut. The 
stent has a length L of 16m, an outer diameter D of 1.2mm, a thickness s of 0.1mm, five 
slots in the longitudinal direction and 12 lots in the circumferential direction with length l 
of 2.88mm, and a metal/artery index of 0.3 (Fig. 3.2). The results showed that 
geometrical parameters have a remarkable influence on the mechanical characteristics of 
Palmaz-Schatz stent during free expansion. It was shown that a lower metal-to-artery 
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surface ratio, in particular, contributes to higher rates of radial and longitudinal recoil and 
lower rates of dog-boning effect. The model with metal-to-artery ratio of 0.3 shows 2.9% 
of recoil, 6.69% of foreshortening and 27.87% of dog-boning, whereas the model with 
1.46 shows 1.74% of recoil, 11.97% of foreshortening and 66.33% of dog-boning. 
Furthermore, the impacts of geometries of two stents (Carbostent and Multi-Link Tetra) 
on their mechanical performances were compared and Fig. 3.3 shows the geometries of 
two stents.  
 This study has revealed the potential of FEA in evaluating stent performance and 
conducting an optimization for stent geometry, which is considered as the first 
attempt to have simulated the future generation stents. However, the results are 
focused on only strut itself as a perspective view of recoil, foreshortening, and 
dog-boning. Even though the recoil, foreshortening, and dog-boning phenomena 
have significant contributions to the rate of ISR, the direct stress evaluation on the 
artery and plaque should be more important. 
 
 
Fig. 3.2 Geometry of the unexpanded stent strut; l: length of the slot, s: thickness, αp: 
angle described by the metallic surface, αv: angle described by the slot and D: outer 
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diameter; finite element mesh for a quarter of stent model (Figure adopted from Miglia 
Migliavacca et al., 2002 [2]). 
 
 
 
Fig. 3.3 Two models of commercial stents. The former is Multi-Link Tetra, and latter is 
Carbostent [2]. 
 
1.3 Chua et al., 2004 [3] 
Chua et al. [3] introduced the results from a similar study that had conducted to 
evaluate the effect of geometrical parameters including the number, width, and length of 
individual stent cells on deployment characteristics of Palmaz-Schatz stents during free 
expansion. In this study, however, they applied pressure load to inner surface of 
cylindrical balloon, not to the stent platform itself. Fig. 3.4 shows the finite element 
models of one-eighth of the slotted tubes for the five designs after meshing. In their 
results, it has been shown that the width and length of the stent cell are not strongly 
related to the diameter and foreshortening of the stent but they contribute to the rate of 
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elastic recoil that diminishes as the number of cells increases and the uniformity of cell 
distribution increases. The maximum deployment pressure for 4 designs varied from 7.08 
mm to 7.886 mm, whereas the elastic recoil varied from 12.23% to 19.70%.  
 This study is important because it is thought as one of the first simulation models 
to incorporate a balloon component within the model system. However, the 
transient behavior of stent was not observed and analyzed even though the balloon 
inflation was driven by pressure control. Furthermore, the geometry variation of 
balloon was not carried out, and the effect of balloon geometry was not included 
in the analysis. 
 
 
Fig. 3.4 Four FEA models of stents with different geometries [3]. 
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1.4 Lim et al., (2008) [4] 
Lim et al. (2008) [4] presented results from a study of the deployment 
characteristics of several different stents during free expansion. The objective of the 
study was to identify potential stent design parameters capable of reducing the possibility 
of ISR driven by foreshortening and dog-boning. The study simulated 3D numerical 
models of seven commercial stents with tri-folded catheter balloon. The interesting point 
on the methods used was that the catheter balloon was discretized by a number of shells 
and fluid elements. Then, the expansion of each stent was achieved through a volume 
control process. Validation of this approach was accomplished by comparing predicted 
pressure–diameter relationships to experimental data reported in the literature (Dumoulin 
and Cochelin 2000 [1]; Migliavacca et al. 2005 [5]; Wang et al. 2006 [6]). Similar 
expansion profiles were observed for each stent, and predicted rates of foreshortening and 
dog-boning were measured. The study noted that the stents with closed unit cells 
connected by straight-line links elements had generally higher rates in foreshortening and 
dog-boning than those with open unit cells connected by bend-shaped link structures. 
 This study provides a first look at the realistic transient non-uniform balloon-stent 
expansion by investigating the mechanical properties, behaviors, and design 
parameters capable of reducing the possibility of restenosis risk induced by the 
foreshortening or the dog-boning. The authors adopted the pressure control with 
explicit method to observe the transient behavior of stent and show the results of 
foreshortening and dog-boning rate. However, the relationship between the rate of 
foreshortening and ISR is unclear. Moreover, not only artery and plaque 
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components are excluded, but also the consideration of coating polymer is omitted 
in their model. 
 
1.5 Hopkins et al., (2010) [7] 
Hopkins et al. (2010) [7] introduced the novel approach to express the coating 
delamination behavior by adopting cohesive zone model. In this paper, the cohesive zone 
model of the stent-coating interface is implemented to investigate coating de-bonding 
during stent deployment. Simulations reveal that coatings de-bond from the stent surface 
in tensile regions of the plastic hinge during deployment. The critical parameters 
governing the initiation of delamination include the coating thickness and stiffness, the 
interface strength between the coating and stent surface, and the curvature of the plastic 
hinge. The coating is also computed to de-bond from the stent surface in compressive 
regions of the plastic hinge by a buckling mechanism. The results showed that the 
computed patterns of coating delamination correlate very closely with experimental 
images. 
 This study is regarded as the first attempt to include the coating component into 
the FEA model and address the point of focus on the coating component. The 
authors successfully demonstrated the coating delamination phenomena using the 
cohesive zone model. However, this study also has several limitations. The model 
was developed based only on the single hinge area with the 2D analysis 
perspective and very simplified boundary conditions. 
 
2. Models with Arterial Wall System 
46 
 
 
 
Experimental evidence indicates the mechanical interaction between the stent and 
the artery as a significant cause for the activation of ISR. According to these 
considerations, the aim of this sub-section is to review the biomechanical interaction 
between a balloon-expandable stent and a stenotic artery, highlighting considerations able 
to improve the general understanding of the problem. To date, several studies have been 
carried out to investigate how geometrical properties, material properties, and 
deployment methods affect the expansion characteristics and biomechanical impact of 
stents when deployed within both normal and occluded coronary arteries. 
 
2.1 Auricchio et al., (2000) [8] 
Auricchio et al. [8] examined the deployment characteristics of a Palmaz–Schatz 
stents when they are expanded within an idealized stenotic artery. The stenotic artery was 
modeled as a cylindrical vessel with a parabola-shaped plaque. Fig. 3.9 shows the final 
configuration of the stent and the artery after the balloon deflation. Both the artery and 
the plaque were simplified as isotropic, homogeneous, incompressible materials, and 
their mechanical behaviors were approximated using the hyper-elastic constitutive 
models based on the data reported in the literature (Hayashi and Imai 1997) [9]. The 
expansion of the stent was achieved through the application of a pressure load on its inner 
surface, and a number of stent deployment characteristics such as elastic recoil, 
foreshortening and metal-to-artery ratio were calculated. As a result, the numerical 
outcomes were validated against experimental data in the literature proving that the 
deployment of a stent within a vessel may be accurately simulated using the FEA.  
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 This study is regarded as one of the first attempts to utilize FEA in analyzing the 
expansion of stent within a stenotic artery environment. Furthermore, it has an 
important meaning that the artery and plaque components were expressed as 
adopting hyper-elastic constitutive models which are continuously utilized in 
further studies. However, this study also has a critical limitation that the stress 
analysis on artery and plaque wall has not been conducted. The developed model 
only takes the mechanical behaviors of stent itself into account.  
 
  
Fig. 3.5 The finite element stent model including a stenotic artery component [8]. 
 
 
2.2 Chua et al., (2004) [10] 
Chua et al. [10] developed a model to evaluate the deployment characteristics of a 
Palmaz–Schatz stent under an idealized stenotic artery and to assess the degree of stent-
induced arterial stresses accumulated in the vessel. The stenotic artery was modeled as a 
cylindrical vessel with a parabola-shaped plaque. Artery and the plaque were simplified 
as homogenous, isotropic and incompressible materials, and their mechanical behavior 
was predicted using linear elastic material models based on data reported in the literature 
(Veress et al. 2000) [11]. Fig. 3.10 shows the entire assembly of the model for the balloon 
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catheter, slotted tube stent, plaque and arterial wall. The expansion of the stent was 
achieved through the application of a pressure load on the inner surface of an idealized 
cylindrical balloon. It was observed that the regions which were subject to the highest 
stresses in the stenotic artery coincided with places where the most plaque ruptures have 
been reported. Also, the study confirmed that the maximum diameter achieved when the 
stent was expanded within the stenotic artery was significantly smaller than that during 
free expansion. Although the behavior of the stenotic artery was idealized using linear 
elastic material models, the results clearly identify the possible regions of high stresses 
that may be induced during stent deployment within a stenotic artery.  
 This study is considered as the first attempt to assess the degree of stent-induced 
arterial stresses incurred in the vessel and to contain the balloon component in the 
model. The von-Mises stresses on the artery and plaque wall have been analyzed 
and the mechanical performances of stent, such as recoil and foreshortening, were 
also investigated. However, the geometrical parameterization analysis was 
excluded and the model was developed with only one-fourth of its model using 
symmetrical boundary condition. With the consideration of BMS (not DES), this 
study has developed the cornerstone of FEA model for further studies with artery 
and plaque components.  
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Fig. 3.6 Finite element model of the assembly with balloon component [10]. 
 
 
2.3 Holzapfel et al., 2005 [12] 
Holzapfel, Stadler, and Gasser (2005) [12] simulated three different stents 
expanded in a patient-specific model of stenotic artery and investigated the effects of 
various geometrical parameters such as stent cell dimensions and strut thickness on the 
biomechanical impacts of the stents. Three stent designs based on respectively, Multi-
Link, NIR, and In Flow Gold stents, were considered in the study. Fig. 3.12 shows the 
geometrical parameters of 3 different stents. A realistic model of a stenotic artery was 
generated using magnetic resonance images of an actual iliac artery. The properties of 
several sections of the stenotic artery were defined using a number of hyper-elastic 
constitutive material models based on experimental data (Holzapfel et al. 2000) [13]. The 
pressure load on the inner surfaces of the stents was the driving force behind the 
expansion within the vessel. The results of this study were used to investigate the 
influences of mismatch (see Fig. 3.13), strut thickness, and cell geometry on intimal 
pressure concentrations and the degree of stent-induced arterial stresses. Based on the 
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investigated stenosis and the performed parameter studies it reveals that the best results 
for all three indicators can be achieved with stent S1 whereas the worst results were 
achieved with stent S3.  
 The major strength of this study could be considered as the incorporation of 
patient customized artery model. In addition, this study is regarded as the first 
attempt to conduct the stent geometry parameterization analysis in inclusion of 
artery and plaque components. Adopting three different commercial stent models 
for result comparison is similar to the approach in the current thesis. However, the 
consideration of recoil and coating component is excluded, which could be a 
limitation of this study.  
 
 
Fig. 3.7 Three different stent geometries described by a number of parameters, denoted 
by lowercase letters. (a) Multi-Link TetraTM stent (Guidant): S1, (b) NIROYALTM-
Elite stent (Boston-Scientific): S2, (c) InFlow-Gold-FlexTM stent (InFlow Dynamics): 
S3 [12]. 
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Fig. 3.8 Mismatch ΔM=D-M between the smallest lumen diameter M in the stenosis and 
the diameter D of the expanded stent. The lumen diameter of the healthy arterial region is 
characterized by L [12]. 
 
 
3. FEA for Stent Modeling 
3.1 Computational methods 
3.1.1 Numbers and types of meshes 
Determining the number of meshes (or elements) in FEA model is a critical step 
due to the cost issue for computation. At the early stage of previous FEA studies, the total 
number of meshes is relatively small compared to the current stage of work since they 
tend to focus on single curve or unit cell instead of a full complete model of stent. They 
generated meshes from dozens to hundreds and the maximum number of the meshes was 
up to thousands. Over time, the aggregate number of meshes has been increased with the 
remarkable development of computational resources. Nowadays, nearly millions of 
meshes can be created, which leads the range of researcher’s focus to expand to the full 
model of stent. However, even with current technologies and computational resources, 
the total number of meshes could easily overshoot a couple of millions when we apply a 
multiple components such as arterial wall, plaque and/or polymer coating. Therefore, an 
optimizing the number of meshes still remains as an important step for conducting an 
FEA computation. 
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Fig. 3.9 Types of mesh. (a) Hexahedral and (b) Tetrahedral 
 
 On the contrary, the types of mesh seem not to have a tendency over time. There 
are two dominant types among the mesh, hexahedral and tetrahedral mesh (see Fig. 3.18). 
In general, the hexahedral mesh is preferred for any given analysis since the total number 
of elements, in the same density, is much less than that of tetrahedral. However, 
tetrahedral mesh has an advantage in terms of its usability and convenience of creating 
good quality of mesh. In the area of FEA for stent, even though the majority of studies 
adapted hexahedral meshes, the simulations of FEA using tetrahedral mesh show 
relatively accurate results which indicates the result seems irrelevance with selecting a 
type of mesh. 
 
3.1.2 Element types 
A number of types of elements can be used in FEA, but in modeling stents with 
FEA, three element types are generally used; 3D solid element, 2D shell element, and 2D 
membrane element. For most of the components in stent systems except for the coating 
and/or balloon components, a 3D solid element is employed. In general, 2D shell element 
and 2D membrane element are used for the coating component and balloon component, 
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respectively. However, there are some studies that have adopted 3D solid elements for 
the balloon component [4,12]. The 3D solid element has an advantage on evaluating the 
stress along the cross-section direction although it requires a high level of computational 
resources due to a massive amount of nodes for the same mesh size. There was a study 
using 1D or 2D elements instead of the 3D to reduce the problem size [6]. Although the 
results of them are not exactly same, it turned out that those elements in three different 
dimensions showed the similar results. 
With the recent development of computational technologies and resources, the 
maximum number of the elements to be calculated has been enormously increased. In 
addition, reduced integration point method, one of the options for computing the elements 
in FEA, can save the computational costs.  
 
3.1.3 Boundary conditions 
To reduce the computational costs, a symmetric boundary condition is often 
applied in FEA. In imposing the symmetric boundary condition, the nodes belong to a 
symmetric plane are required to have zero displacement in the direction normal to the 
symmetric plane. To prevent rigid-body motions, a set of nodes at the distal end of an 
artery or stent platform are constrained to move to the longitudinal direction so as to 
ensure free expansion in the radial direction. In the loading conditions with displacement 
control, any constraints for the nodes are not necessarily required to prevent rigid-body 
motions whereas the pressure control does. 
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3.1.4 Displacement and pressure control methods 
Stent expansion is generally operated through the displacement control or 
pressure control. The displacement control method is to apply the displacement boundary 
condition onto the inner surface of stent strut along the radial direction using cylindrical 
coordinate system while the pressure control method is to apply an internal pressure onto 
the inner surface of a stent or balloon. When a study focuses on evaluating the stress 
distribution on every component regarding the convenience of reaching convergence, 
adopting the displacement control is likely to be preferred.  
 In the meantime, the pressure control method is often combined with the explicit 
method to choose, which enables the observation of transient behaviors of a stent during 
the expansions, such as dog-boning and foreshortening phenomena. However, this 
method normally requires much longer computational time since smaller increments, 
compared to the displacement control method, are needed to stabilize the dynamic 
behaviors and interactions between the components.  
 
3.2 Material properties and geometrical parameters 
The dominant aim of previous studies was to evaluate the influences of 
geometrical parameters and material properties of stents on their mechanical behavior 
during deployment. The followings provide the summaries of stent/balloon geometry 
effectiveness of various models. 
 In comparison of tubular stent and coil stent, the result from FEA showed 
that tubular stent is very rigid and coil stent is significantly more flexible, 
and the stresses are locally concentrated at the link nodes.  
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 Lower metal-to-artery surface ratio contributes to higher rates of radial as 
well as longitudinal recoil and lower rates of dog-boning effect. 
 The width and length of the stent cell are not strongly related to the 
diameter and foreshortening of the stent, but they contribute to the rate of 
elastic recoil that diminishes as the number of cells increases and the 
uniformity of cell distribution increases.  
 The stents with closed unit cells connected by straight-line links elements 
had generally higher rates in foreshortening and dog-boning than those 
with open unit cells connected by bend-shaped link structures. 
 Both proximal/distal stent strut geometry and balloon length have a 
significant effect on the degree of dog-boning exhibited during stent 
deployment. 
 Large stent strut-spacing, radius of strut curvature, and axial ring 
amplitude are associated with lower levels of stent-induced arterial stress. 
 The material properties of a plaque have a significant influence on the 
underlying arterial stresses induced during stent deployment with stiffer 
plaques playing a protective role during stent deployment. 
 
3.3 Limitations of previous works 
 As described in the previous sections, a number of studies for stent modeling with 
FEA have been conducted so far. Many researchers have been trying to optimize the 
geometry of stent and loading methods of balloon catheters. At the early stage, it is true 
to say that majority of their work were concentrated on the mechanical performance of 
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stent such as foreshortening and/or dog-boning. Over time, few studies started to focus on 
the stress on the artery and plaque which could quantitatively describe the rate of ISR, 
indirectly. Unfortunately, the targets of those works are mostly focused on BMS in spite 
of the fact the majority of stent medical devices tend to move to next generation of DES. 
In other words, most of prior research has focused on the mechanical performance of 
BMS and models including 3D coating components have not yet been developed. 
The research in this thesis improves on existing models by: 
 Incorporation of 2D and 3D drug-polymer coating components to develop 
integrated DES model which enables the evaluation and investigation of 
von-Mises stresses on artery, plaque, coating and stent strut. 
 Full 3D DES model without symmetric boundary condition. 
 Comparison of three different commercial DES including the most 
recently released products. 
 Provision of novel methods to analyze and predict the accurate location of 
stress concentrated area within 3 commercial DES.  
 Various stress components analysis on drug-polymer coating element. 
 Suggestions of quantitative values of bonding strength between stent strut 
and coating components. 
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Chapter 4. FEA Computations 
 
 A typical FEA of stent deployment involves a number of the important pre-
processing stages. The first step is to generate the geometries of the components and to 
create the meshes that are incorporated into the FEA. These FE meshes are routinely 
obtained directly from the computer-generated solid models using the mesh generation or 
discretization algorithms. The material properties for each individual component must be 
defined and the appropriate boundary and loading conditions must be applied to them. 
Finally, a suitable solution methodology must be chosen. In this chapter, these FEA 
computation steps are articulated and discussed. 
 
1. Model Stent 
 In the FEA computations, the first stage is to generate a suitable solid model for 
each individual constituent component. In an FEA of stent deployment, the solid model 
for a stent platform, catheter balloon, and stenotic artery may be required. Once 
generated, these solid models must be discretized into acceptable FE meshes. Since most 
stents have complicated geometrical designs, and strict patent claims keep the 
information about commercial stents from being distributed, the generation of the solid 
model for a stent is not an accommodating task.  
 One strategy that has been utilized to develop FEA meshes for a number of stent 
designs involves cutting an actual stent along its longitudinal axis and measuring the 
important geometrical properties such as strut width, thickness, and length using a 
microscope. Using these measurements, the model of the planar stent geometry can be 
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reasonably defined within a FEA package. This model can be discretized into a suitable 
amount of meshes and rotated into its cylindrical configuration by the coordinate 
transformation as shown in Fig. 4.1 [1]. Another strategy that has been adopted in recent 
years is using X-ray tomography to generate a detailed 3D model of the stent of interest.  
For a complex stent design, with using this approach, highly accurate FE meshes can be 
generated. 
 In general, the stent model can be simulated into two different element types, 3D 
solid and 2D shell element. The 2D shell element can save much computation costs since 
they allow modeling a thin feature with a relatively less amount of elements than the 
solid element. They are also easier to mesh and less prone to negative Jacobian errors that 
might occur when used for extremely thin solid features such as balloon. Stent solid 
models are generally discretized using solid elements. In practice, a stent is crimped and 
loaded upon a balloon that is both tapered and folded onto a catheter. In the studies in 
which the expansion of the stent has been simulated through balloon dilation, the catheter 
balloon was generally modeled as an idealized cylindrical surface and discretized using 
the shell elements [1]. In this study, since the existence of balloon component is 
neglected, all of the components (except the coating) in the model are constructed with 
full 3D solid elements. Generally, in the studies that have evaluated the expansion of a 
stent within a normal and stenotic artery, including this thesis, the artery and plaque were 
modeled as an idealized cylinder and discretized using the solid elements [1]. 
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Fig. 4.1 'Wrapping' of planar stent geometry (top) into its cylindrical configuration 
(bottom) (figures adopted from [1]). 
 
2. Material Properties 
 Before conducting any FEA computation, the material properties of each 
component in the system must be adequately defined. As discussed in the previous 
chapter, coronary stents platforms are generally manufactured using a biologically inert 
metallic material such as medical grade 316L stainless steel. In this thesis, model B 
(TAXUS Express2 stent) and model C (Biomatrix FLEX) have adopted 316L stainless 
steel as the material for stent strut, whereas model A (SYNERGY stent) is consisted with 
Pt-Cr alloy. The behavior of these materials is elastic–plastic in nature and their response 
to uniaxial loading could be highly non-linear. In the majority of the previous FEA 
studies, in this study as well, the stent materials were simplified as homogeneous and 
isotropic, and their behaviors were typically defined using bilinear and multi-linear 
plasticity models with isotropic hardening [1]. These plasticity models are incorporated in 
most commercial FE packages, and they can be generally, defined using the data obtained 
from an experimental test. The incorporation of the relevant mechanical behaviors of an 
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arterial tissue has been a difficult task due to the non-linear, anisotropic, stress-stiffening 
nature of the biological material. In the majority of the previous studies as well as this 
thesis, the arterial tissue was approximated as a homogeneous, isotropic, and 
incompressible material, and its behavior was defined using a hyper-elastic constitutive 
model [1]. The hyper-elastic model assumes an ideal elastic material for which the stress–
strain relationship is derived from a strain energy function. The strain-energy function is 
the measure of the energy stored in a material as a result of its deformation, and it is 
generally fitted to the data obtained from experimental testing of the arterial tissue. Fig. 
4.2 shows the example of stress-strain curve of the hyper-elastic model for an arterial 
wall [2]. Most commercial FEA packages include a number of hyper-elastic constitutive 
material models with suitable curve-fitting applications that are capable of capturing the 
mechanical behaviors of a biological material. 
 
Fig. 4.2 An example of stress-strain curves for the hyper-elastic models. (Adopted from 
[2]) 
 
3. Boundary and Loading Conditions 
 To predict the reliable results, the boundary and loading conditions of a FEA 
mesh should be realistic to closely akin to the actual conditions in question. In analyzing 
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stent deployment, the stent should be free to expand and contract in the radial and 
longitudinal directions except for the fixed position to prevent rigid-body motions. 
Generally, a set of nodes located in distal end of each discretized component are 
constrained from the displacement in a longitudinal direction to avoid any rotational or 
translational movement. However, in case of our study, additional boundary conditions to 
prevent rigid body motion are excluded because we applied the displacement control as 
the loading method. In case of the model with the symmetric boundary condition, it is 
required that the nodes belonged to a symmetric plane have zero displacement in the 
direction normal to the symmetry plane. Such symmetric conditions were not 
implemented in our computation because we used the full 3D models of DES system. 
 For the loading condition, stent expansion is typically achieved using two 
methods, displacement control and pressure control. The studies in which the stent 
expansion was achieved through the displacement control have involved the expansion of 
an analytical surface within the stent while the studies in which the stent expansion was 
achieved through the pressure control have involved the application of a pressure load on 
the inner surface of the stent [1]. Both displacement control and pressure control loading 
methods have their own characteristics, and depending on the aim of a study, one of two 
methods is typically selected. The displacement control has a strong advantage with the 
easiness of computational convergence, and it could be coupled with either implicit or 
explicit methods. This loading method is generally used when the aim of a study is to 
evaluate the stress distribution along the stent strut, coating and arterial wall. However, 
this method has the limitation that the final displacement of stent deformation must be 
pre-determined with given information and the transient status of the stent expansion 
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could not be observed. The pressure control can be also operated with both of implicit 
and explicit methods, and has an ability to obtain stress distribution results for any 
components. However, unlike displacement control, applying pressure control with 
implicit method is often computationally unstable and needs further stabilizing factors for 
convergence of the solutions. Hence, normally, pressure control is performed with 
explicit method. The pressure control is preferred when the aim of study is focused on the 
transient phenomena such as dog-boning and foreshortening of stent platform. Fig. 4.3 
shows examples of FEA computations from the current thesis using displacement and 
pressure control methods. Note that we did not apply the pressure control in our 
computations; the image shown in Fig. 4.3(b) is only for the visualization purpose. The 
arrows represent the position and direction of displacement imposed in the simulation. 
Note that the arrows in pressure control are located in the inner side of stent platform.  
 
                   (a) Displacement control                             (b) Pressure control 
Fig. 4.3 Cross-sections of stents to show two different loading methods, (a) displacement 
control and (b) pressure control. 
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4. Solver Method 
 The final step in the pre-processing stage of a structural FEA is the selection of a 
solution methodology that calculates the nodal displacements, stresses, and strains.  This 
procedure is very last and critical step in pre-processing stage. Typically, stent 
deployment has typically used either implicit or explicit solution method. The 
comparison of these two methodologies must be clearly understood. A non-linear implicit 
structural analysis does not consider dynamic effects; however, due to the presence of 
large deformations in the analysis, a solution is generally obtained over a series of sub-
steps to ensure numerical stability. During each sub-step, a fraction of the loading 
conditions is applied and the final solution is obtained in a piecewise fashion. Most 
commercially available FEA packages incorporate a Newton–Raphson iterative solver for 
solving non-linear static structural problems which is adopted in this thesis as well [3].  
 In an explicit analysis, the loading conditions are applied over a number of time 
steps and a solution is obtained through a time-integration procedure. During explicit 
time integration, the solver will increment a time step and determine if the loads applied 
to the structure are in equilibrium with the internal forces. Nodal accelerations are 
calculated directly from Newton’s second law and a solution is obtained on an element-
by-element basis [3]. As mentioned in the previous section, the analysis using pressure 
control with explicit method relatively provides a good convergence of calculation since 
the governing equation of explicit method has an acceleration term that is one of the most 
differentiated properties from the implicit method. If the model contains complicated 
interaction constraints, such as contact or collision, the calculation with implicit static 
method easily becomes unstable. In summary, it is generally thought that the implicit 
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method is preferred when the model is established to obtain the result of stresses 
distributions on every component without transient behavior consideration, whereas the 
explicit method is used to observe the transient phenomena such as dog-boning and 
foreshortening effect. 
 
5. Issues in Computational Model Development 
 Other than the computational convergence issues that were previously addressed, 
it is considered that the multi-scale and material property issues are one of the most 
challenging roadblocks to overcome in developing more advanced FEA models. 
  
5.1 Multi-scale issue 
 In general, creation of a good mesh with high quality is critical in the FEA 
computation since it’s directly highly related to the accuracy of results. There are several 
criteria to measure the quality of mesh such as Jacobian and skew, and the most 
important factor is the aspect ratio in the shape of FE mesh. Keeping an aspect ratio 
below 6.00 is highly recommended to obtain reliable results.  
For this reason, if the geometry of a component is like a thin-film, a massive 
amount of elements should be generated. Unlike previous studies, the present study 
includes the coating component with full 3D solid elements (as well as 2D shell 
elements). The typical thickness ratio of drug-polymer coating to stent platform strut is 
small (e.g., < 0.1), hence very large amount of elements must be created to maintain the 
proper aspect ratio. Fig. 4.4 shows an example of the FE meshes created in this study to 
incorporate such multi-scales. In the figure, the cross-section of stent platform strut is 
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displayed, showing coarse platform and fine coating meshes. Another problem resulted 
from this multi-scale issue is the contact interaction between outer surface of coating 
component and inner surface of plaque component. In a technical point of view, the mesh 
density ratio of master surface to slave surface should be in the range of 2 to 1. Here, the 
slave surface is defined as the surface that are moving toward a different surface, called 
as the master surface. With this constraint, generation of large number of elements for 
plaque must be involved as well. To resolve these problems, applying 2D shell elements 
to the coating component could be one of the solutions. The total number of nodes and 
degree of freedom (DOF) significantly decreases even with same density of elements so 
that the computational costs will be decreased.  
 
Fig. 4.4 Cross-section of stent strut to show the dual-scale mesh issue. Coarse and fine 
mesh sizes are required for stent platform and coating materials, respectively. 
 
5.2 Inaccurate/unidentified material properties 
 Needless to say, applying proper material properties to individual components in 
the FEA system is most likely to be an essential step of FEA. In the FE package, elastic 
modulus, Poisson’s ratio, density (explicit only), and stress-strain curve data are required 
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to simulate the model properly. Especially, the stress-strain curve is a key requirement 
property to realize the elastic and plastic behavior of model. In the case of well-known 
materials, such as stainless steels (i.e., 316L), it is not difficult to find the appropriate 
material properties. On the contrary, it is very challenging to obtain stress-strain curves of 
the materials that have been recently invented or are used in a small part for a specialized 
purpose. For this reason, in the current thesis, a bi-linear stress-strain behavior has been 
assumed for the values of elastic modulus, yield stress, tensile strength, and elongation of 
Pt-Cr alloys [4]. In addition, the drug-polymer coating was approximated as a pure 
polymer material. Proper friction coefficient between coating material and plaque is also 
unknown, thus, frictionless surfaces have been considered in our model. 
 
6. Current model and methods 
 Some general aspects of FEA computational model development have been 
described up to this point. In the following sub-sections, we detail our FEA model 
development including geometry generation, material properties, boundary and loading 
conditions, and simulation conditions. Note that all of computations were conducted 
using commercial ABAQUS FEA package. 
 
6.1 Stent Model 
 A 3D FEM model of a typical tubular-shaped intravascular stent (SYNERGY, 
Boston Scientific, Intervention Cardiology, MA, USA) was developed to investigate the 
effects of different geometrical features (such as thickness of strut and coating 
component) on the mechanical behavior of the stent. The models were created by means 
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of computer-aided design considering the commercial stent products; SYNERGY stent, 
TAXUS Express2 stent and Biomatrix FLEX stent (see Fig. 4.5). Practically, it is very 
challenging to perform an accurate biomechanical modeling for expanding process of 
stent delivery system in vivo. The overall response of the system is highly nonlinear due 
to the large amount of deformations in each component and due to the interactions 
between adjacent components. For this reason, in this study, only the stent platform, 
drug-polymer coating, and their interaction were considered to expedite the simulation. 
To reduce the high computational cost of the stent expansion, 7 rings of each stent 
platform were taken into account. 
 
 SYNERGY TAXUS 
Express2 
Biomatrix 
FLEX 
Inner Diameter(mm) 2.29 2.08 3.0 
Strut Thickness (Radial, mm) 0.08 0.132 0.112 
Coating Thickness(µm) 7 22 10 
Longitudinal Length(mm) 8.286 9.280 18.52 
Number of Links 12 18 18 
Number of Rings 7 7 7 
Table 4.1 Geometrical specifications of three commercial stent models incorporated in 
the present thesis [5]. 
 
 Three different coronary stent designs were considered in this study, and they 
resemble three commercial intravascular stents. In the following document, they will be 
referred to as model A (TAXUS Express 2, 2004, Boston Scientific, Intervention 
Cardiology, MA, USA), model B (SYNERGY, 2013, Boston Scientific, Intervention 
Cardiology, MA, USA), and model C (Biomatrix FLEX, 2010, Biosensors International, 
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Singapore), respectively (see Fig. 4.5). The geometrical specifications for these three 
commercial products are summarized in Table 4.1. 
 
 
Fig. 4.5 Stent models to display SYNERGY stent (Model A), TAXUS Express2 stent 
(Model B), and Biomatrix FLEX stent (Model C). 
 
 Fig. 4.6 shows the geometrical shapes of the models from our study. The unit 
model of SYNERGY stent (model A), which is considered as reference model in the 
current work, contains 7 rings connected by 12 links. The inner diameter in the 
unexpanded configuration is 2.299mm while the thickness of the stent strut is 0.08mm. 
The length along longitudinal direction is 8.286 mm and the thickness of coating layer is 
7 µm. The unit model of TAXUS Express stent (model B) is composed of 7 rings 
connected by 18 links. At the initial step, before dilation, the inner diameter was set to 
2.08 mm, the strut thickness was 0.132 mm, longitudinal length was 9.280 mm, and the 
coating thickness was 22 µm. The geometrical dimension of TAXUS stent shows much 
thicker platform struts and coatings compared to the thicknesses of the others. The 
modern trend in DES technology is apt to be thinner strut to reduce the probability of 
occurrence of the side effects such as restenosis or thrombosis. The composition of unit 
model of Biomatrix FLEX stent has 7 rings and 18 links as well. The initial diameter of 
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the FLEX is 3.0 mm, and the strut thickness is 0.112 mm. The thickness of coating 
component is 10 µm which is thinner than that of TAXUS but thicker than that of 
SYNERGY. The longitudinal length is 18.52 mm.   
 
 
Fig. 4.6 Illustrations to show the geometrical factors of 3 commercial stents models; (a) 
SYNERGY, (b) Taxus Express2 and (c) Biomatrix FLEX. 
 
6.2 Geometry and mesh generation 
 During pre-processing, the full 3D FEA models of three different stents were 
generated using two commercial software, Rhinoceros® 5.0 (Robert Mcneel & 
Associates, Indianapolis, IN, USA) and Hypermesh 11.0 (Altair Engineering, Inc., USA). 
Since the difficulties of obtaining the manufactures’ specifications on the actual 
dimensions, the measured dimensions based on digital images were used in this study. 
These measured dimensions were transferred to create the geometrical models of stent 
devices using Rhinoceros® 5.0. After the basic structural drawing of stent model has been 
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generated, the result file is imported to Hypermesh, mesh generating software (see Fig. 
4.7). The stent strut model was meshed using the first order 8-node brick element of 3D 
continuum solid (C3D8R) which supports linear and nonlinear large plastic deformation 
of model, while the coating component model was meshed using the first order 2D 4-
node shell element of S4R which fits analyzing very thin layer. The total numbers of 
elements for model A, model B, and model C are 946521, 431473, and 905917, 
respectively. These higher numbers of elements could be applied in view of the rapid 
development of recent computation technologies. The number of element is very 
important because it is directly related not only to the computational costs but also to the 
accuracy of the results. The simulation conditions for the models in this study, especially, 
have very large nonlinear plastic deformation, which requires to make the mesh as fine as 
possible to maintain the quality. The computation time for a single job in this study is up 
to 2 days, using parallelized computing scheme that utilizes 32 CPUs with 128 GB of 
memory. 
  
 
Fig. 4.7 Structural drawing of stent from CAD software (left) and generated full 3D 
elements mesh (right) 
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6.3 Material properties 
 For the model A (SYNERGY stent), Pt-Cr alloy is used for stent platform and 
poly(lactic-co-glycolic acid) (PLGA) is used for coating polymer material. Pt-Cr alloy is 
most recently developed material that possesses various advantages such as higher yield 
strength and radiopacity. In this Pt-Cr alloy, the weight percentage is 33% for Pt, 18% for 
Cr, 9% for Ni, 2.63% for Mo, 0.001% of C and rest for Fe [4]. The Young’s modulus is 
203 GPa, the Poisson’s ratio is 0.3, and yield strength is 480 MPa [4].  Pt has already 
been used in a number of cardiovascular and neurovascular implantable devices, where 
its inert behavior and high radiopacity have been the key drivers in its selection [4]. The 
tensile properties and density of this Pt-Cr alloy compare favorably with stainless steel 
metal. This enables stent designs with both thin struts and high radiopacity. The material 
for coating component of model A, the biodegradable polymer PLGA is used. These 
days, the PLGA has been one of the strongest candidates for bio-implantable substance 
due to its advantage on biodegradable and biocompatible property. Although PLGA 
shows much brittle characteristics compared to styrene-isobutylene-styrene (SIBS), 
which causes delamination or fragmentation phenomenon, it is more preferred since its 
bioabsorbable nature. The Young’s modulus, Poisson’s ratio, and yield strength of PLGA 
are 1.58 GPa, 0.3, and 29.68, respectively [6].  
 For the model B (TAXUS stent) from Fig. 4.6, 316L stainless steel and SIBS are 
applied to the strut and the coating component, respectively. For 316L stainless steel, the 
Young’s modulus is 201 GPa, the Poisson’s ratio is 0.3, the yield strength is 330 MPa [7]. 
For the coating component, SIBS has been widely used for drug carrier for DES system 
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because of its elastic property.  The Young’s modulus is 0.002 GPa, the Poisson’s ratio is 
0.49, and the yield strength is 0.5 MPa [8].  
 The 316L stainless steel has been also used as material for strut platform of the 
model C (FLEX stent) in Fig. 4.6. While model B and C have the same material for strut, 
the model C has biodegradable polymer drug carrier which is called poly(lactic acid) 
(PLA). The elastic modulus of PLA is 1.30 GPa,   the Poisson’s ratio is 0.3, and the yield 
strength is 50.96 MPa, respectively [9]. The physical/mechanical properties of materials 
that were incorporated in our model are summarized in Table 4.2 and the stress-strain 
curves for the materials are depicted in Fig. 4.7 and Fig. 4.8.  
 
Material Young’s Modulus 
(GPa) 
Poisson’s Ratio Yield Strength 
(MPa) 
Stainless Steel 316L 201 0.3 330 
Pt-Cr Alloy 203 0.3 480 
SIBS 0.002 0.49 0.5 
PLGA 1.58 0.3 29.68 
PLA 1.30 0.3 50.96 
Table 4.2 Mechanical properties of materials [4,6-9]. 
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Fig. 4.8 Stress-strain curves for stent platform materials [4,7]. 
 
 
 
Fig. 4.9 Stress-strain curves for three different polymer coating materials [6,8,9]. 
 
The artery and plaque material were defined by a Mooney-Rivlin hyper-elastic 
constitutive equation. Table 4.3 summarizes the coefficients used for the hyper-elastic 
constitutive equation to define the material properties of artery and plaque. 
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 C10[MPa] C01[MPa] C11[MPa] C20[MPa] C30[MPa] 
Artery 0.708 -0.620 0 2.827 0 
Plaque -0.802 0.831 1.157 0 0 
Table 4.3 Mechanical properties of artery and plaque [11]. 
 
6.4 Simulation conditions 
6.4.1 Solver method 
 A large deformation analysis is performed using ABAQUS commercial code 
(Hibbit Karlsson & Sorenses, Inc., Pawtucket, RI, USA) based on the FEA. In general, 
the ABAQUS/Standard program is used in the classical displacement formulation. For a 
highly nonlinear problem, the matrix equation is solved using a Newton-Raphson’s 
method due to the material plasticity and tie constraint. The method for the convergence 
criterion is to ensure that both the largest residual in the balance equations and the largest 
correction to any nodal unknown provided by the current Newton iteration are 
sufficiently small. In general, for the studied problem the convergence is verified when 
the residual force is less than a predefined tolerance (in our case, 0.5% of the average 
force in the structure, averaged over space) and when the largest displacement correction 
is less than a predefined tolerance (in our case, 10% of the largest incremental 
displacement). 
 The numerical computation was performed simulating free expansion of the stent. 
Instead of applying internal pressure (pressure control method) to the inner surface of 
stent, predefined radial displacement condition (displacement control method) was 
applied because the transient behaviors were not analyzed. A surface to surface tie 
constraint is applied as interaction between stent strut and coating materials so that they 
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are moving together throughout the simulation. The inelastic constitutive response is 
described through a von Mises-Hill plasticity model with isotropic hardening employed 
in the ABAQUS FEA software package [10]. 
 
6.4.2 Elements 
 Since the simulation is based on full 3D modeling, the continuum 3D 8-node 
reduced integration hexahedral brick element (C3D8R) is used for both stent struts and 
coating components.  Especially for coating components, not only the 3D brick element 
but also 2D shell element was applied for the comparison purpose. For shell element, 2D 
4-node reduced integration shell element was chosen for coating materials. 
 
6.4.3 Loading steps 
 Determination of an appropriate calculating method, at step module, is one of the 
most critical parts of conducting FEA. ABAQUS contains several types of solver 
methods, but they can be subjected into two different cases, i.e., implicit and explicit 
methods. In our study using ABAQUS/Standard, the implicit static method was used for 
entire set of calculations. ABAQUS/Explicit method is generally preferred when a model 
includes dynamic behavior, such as collision, or has a very complicated contact 
interaction between the parts inside. As mentioned in previous section, implicit static is 
suitable method for our study, since we do not consider the transient behavior of stent 
such as dog-boning and/or foreshortening phenomena. In addition, the contact interaction 
in our model is relatively simple, and the total number of elements is very high. 
Considering these factors, the implicit method was elected in the current thesis. An 
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automatic stabilization tool was used for stable convergence, and the default value of its 
coefficient was set to 0.0002. The maximum number of the increments is 100,000, and 
the size of each increment step is 0.01 and 0.02 for the minimum and maximum values, 
respectively. 
  
6.4.4 Loading and boundary conditions 
 Cartesian coordinate is the default coordinate system in ABAQUS/Standard. 
However, another coordinate system (Cylindrical system), is required to be added before 
considering the loading conditions since the displacement should be applied parallel to 
the radial direction of macroscopic view of stent platform. In the Cylindrical coordinate 
system, the radial displacement was applied to all the nodes on the inner surface of 
platform with the value of 0.687 mm for Model A (SYNERGY stent), 0.624 mm for 
Model B (Taxus Express2 stent), and 0.9 mm for Model C (Biomatrix FLEX stent), 
respectively. The amounts of radial displacements were arbitrary selected to achieve 60% 
of full dilation, because the initial geometries of each stent are different. For the analyses 
with artery and plaque components, the amount of radial displacement was 0.62975 mm, 
which was again arbitrary chosen to achieve 55% of full dilation. As the simulations with 
artery and plaque have same geometry of SYNERGY stent, the amounts of radial 
displacement are equivalent. The loading conditions are summarized in Table 4.2.  
As all simulation models in this study have adopted displacement control, free 
boundary condition is applied. Since no symmetric boundary condition is applied to the 
models in our study, the constraints along the longitudinal and tangential direction were 
not necessary to prevent rigid body motion.  
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Model A 
(SYNERGY) 
Model B 
(Taxus 
Express2) 
Model C 
(Biomatrix 
FLEX) 
Model A with 
Artery & Plaque 
(SYNERGY) 
Displacement 
Increment, 
mm 
0.687 0.624 0.9 0.62975 
Dilation, % 60 60 60 55 
Coordinate 
System 
Cylindrical Cylindrical Cylindrical Cylindrical 
Boundary 
Condition 
Free Free Free Free 
Table 4.4 Loading conditions of each model. 
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Chapter 5. Results and Discussions 
 
In this chapter, the computational results with various parameters will be analyzed   
and discussed. The parameters that we have explored in the current thesis include element 
dimensionality, strut thickness, coating thickness, and stent design. The focus of the 
analysis is primarily on the von-Mises stresses at the maximum location in the 
components of strut, coating, and arterial wall. In addition, the results about the recoil of 
stent deployment is addressed and discussed as well. Most computational results are 
majorly based on the FEA of the model A (SYNERGY stent) system. 
 
1. Results from Computations Using 2D and 3D Coating Elements 
 Before conducting the parameterization study, the prerequisite step is to compare 
the results between using 2D and 3D elements for coating component. For the 3D 
elements, in general, creating a good quality mesh model that has a complicated 
geometry with high aspect ratio is very challenging. Usually, an element with a high 
aspect ratio is considered as a low quality element. When an element is constructed with 
a higher aspect ratio, the shape of the element is distorted, which could cause an 
inaccurate result. Therefore, it is important to maintain the aspect ratio as close to unity 
as possible and to generate a number of elements when the shape of a model is like a 
thin-layer. In the current thesis, the geometrical design of the stent is composed of many 
curvatures, and in the meantime, the thickness of the coating component is very thin 
compared with that of the strut (See Fig. 4.4). Hence, creating a number of elements must 
be accompanied so as to prevent element distortion. For the 2D elements, however, 
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relatively much less number of nodes are needed even the total number of the elements 
are as same as that of the 3D element so that the computation cost could be remarkably 
decreased. Consequently, the result comparison between using 2D and 3D element must 
be carried out before the parameterization study. 
The contour plots of von-Mises stress on the coating component of SYNERGY 
stent (model A, reference model system) using the 2D shell and the 3D solid element 
methods are shown in Fig. 5.1. For the loading condition, the displacement control was 
used, and the amount of the stent expansion in a radial direction was set as 60 % with 
reference to the initial diameter. The maximum location of the stress, as indicated in Figs. 
5.1(a) and (b), does not change for both computations. It is found that the plots based on 
2D and 3D coating elements are nearly identical not only for the location but also for the 
magnitude/distribution of the stress along the coating components.  
 
 
Fig. 5.1 Comparison of stress distribution on the coating of SYNERGY (model A) stent 
using 2D and 3D elements. (a) 2D shell element and (b) 3D solid element. 
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 In general, to evaluate the 6 stress components with the 3D solid elements, it is 
necessary to select a proper element that lies on each component in a perpendicular or 
parallel direction to the axis since the 3D elements follow the global coordinate system 
whereas the 2D elements have its own local coordinate system. Fig. 5.2 shows the 
location of the elements used to investigate the stresses shown in Fig. 5.3 and Fig. 5.4. In 
Fig. 5.3 and Fig. 5.4, we show the profiles of various stress components from 
computations for model A using 2D and 3D coating elements. 
 
 
Fig. 5.2 The location of elements used for comparison of 2D and 3D elements. 
 
It should be noted that six stress components (11, 22, 33, 12, 23, and 13 
directions, where 1, 2, and 3 represent one of the 3D unit directions) can be analyzed by 
using the 3D solid elements. On the other hand, the 2D shell elements, which considers 
plane stress, have only three stress components (11, 22, and 12 directions) since the 
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stresses with normal direction (3 direction) are neglected. In analyzing our results, it is 
more convenient to use the cylindrical coordinate system instead of the Cartesian system, 
i.e., the global coordinate system, defined in ABAQUS/Standard by default. With this 
Cylindrical coordinate system, the stress components could be readily divided into six 
different stress components, such as normal/shear stresses in radial, circumferential, and 
longitudinal directions. Here, we define our system as given in Fig. 5.5. Here, the radial, 
circumferential, and longitudinal directions were specified with reference to the overall 
geometry of stent. The yellow arrow indicates the direction of the circumferential normal 
stress, and the red arrow displays the direction of the radial normal stress. 
From Figs. 5.3 and 5.4, it is clearly seen that the stress component of the 
circumferential normal direction is dominant. The circumferential normal stress curve 
clearly shows the elastic and plastic region. In the case of the 3D elements, all stress 
components except the circumferential stress show the value close to zero, which means 
that their contributions to the magnitude of von-Mises stress have a minor effect. Also, 
the circumferential normal stress shows its dominance in the 2D elements even though 
the radial normal stress shows noticeable amount of its magnitude. The maximum value 
of the circumferential stress was 42.9 MPa for 3D elements and 38.5 MPa for 2D 
elements.  
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Fig. 5.3 Six stress components in the coating of model A using 3D elements. 
 
 
Fig. 5.4 Three stress components in the coating of model A using 2D elements. 
 
 
87 
 
 
 
 
Fig. 5.5 The direction of circumferential and radial normal stresses. 
 
Fig. 5.6 shows the von-Mises stress variation of both cases at the maximum 
location during expansion up to 60% of full dilation. The difference of two maximum 
von-Mises stresses from 2D and 3D element systems at the 60% of dilation, which is 
considered as the complete expansion of the stent, is 0.81%, thus it can be concluded that 
the von-Mises stress distributions based on the 2D and 3D coating elements are similar. 
Based on these comparisons, though there are some differences in the individual stress 
component distributions, it is approximated that all the von-Mises stress predictions in 
the coating components from the 2D and 3D elements are consistent. Therefore, in 
analyzing the von-Mises stress distributions, all the rest of the simulations are performed 
with the coating components with the 2D shell element to reduce the computational costs. 
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Fig. 5.6 von-Mises stresses at the maximum location as a function of % dilation with 2D 
and 3D models of model A. 
 
 
2. Impacts of Stent Strut Thickness 
 The first set of the simulations evinced the strong influence of the strut thickness 
on the von-Mises stress distribution along the surface of both the strut and coating 
components. SYNERGY stent (model A) was used, and the first change of the 
geometrical parameter was the stent strut thickness, and the values of those are set up as 
60 µm, 80 µm, and 100 µm, while the coating thickness is fixed to 7 µm. Fig. 5.7 shows 
the impact of the strut thickness on the von-Mises stress of the strut itself, and all 3 
models are in the same scale with the state of the full expansion with 60% dilation. The 
locations of local maximum stress zone for these three different conditions are similar, as 
indicated by the images in the bottom panels of Fig. 5.7. From the results, it is possible to 
conclude that the red areas that represent relatively high stress concentration increase as 
the strut thickness becomes thicker. This can be explained by the fact that the strain 
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increases if the thickness becomes higher. The maximum magnitude of Mises stress is 
located are on the curves with links. Therefore, it can be considered that these regions are 
the most vulnerable places to delamination and/or fragmentation of coating.  
 
 
Fig. 5.7 Contour plots of von-Mises stress distributions in the stent platform of model A 
with different strut thicknesses. 
 
 Fig. 5.8 shows the linear relationship between the strut thickness and the 
maximum stress. The element chosen for analyzing the simulation in Fig. 5.8 is located in 
the center of the red area from Fig. 5.7. Therefore, it is considered that Fig. 5.8 represents 
the variations of maximum stresses in the systems with 60, 80, and 100 µm strut 
thicknesses. At 60% of dilation, the maximum stresses are 586.9 MPa, 607 MPa, and 
636.7 MPa for 60 µm, 80 µm, and 100 µm, respectively. From this result, the maximum 
local von-Mises stress in the stent strut increases by 8.5 % when the strut thickness 
increases from 60 µm to 100 µm. 
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Fig. 5.8 Plots of von-Mises stress distributions on stent strut. (a) von-Mises stress growth 
with % dilation and (b) Maximum von-Mises stress at the status of full dilation. 
 
 In the next figure (Fig. 5.9), we show the contour plots of von-Mises stress 
distributions on the coating components from the same computations of 60% dilation. 
These results have an important meaning because they show the stress distributions on 
the coating component thoroughly, and the shown maximum stress location could be 
regarded as a vulnerable spot which is prone to be delaminated. The simulation results of 
the coating components fully expanded are shown in Fig. 5.9 on the same scale to 
compare the stress differences. In Fig. 5.10, it is easier to identify that the stresses 
increase as the thickness of the stent strut increases. The location of the maximum stress 
region is the same as its strut. The magnitude of the maximum stress is 43.98 MPa for 60 
µm, 45.34 MPa for 80 µm, and 47.81 MPa for 100µm, respectively. The maximum local 
von-Mises stress in the coating increases by 8.7 % when the strut thickness increases 
from 60 µm to 100 µm. 
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Fig. 5.9 Contour plots of von-Mises stress distributions on the coating component of 
model A with different strut thicknesses. 
 
 
Fig. 5.10 Plots of von-Mises stress distributions on coating component. (a) von-Mises 
stress growth with % dilation and (b) Maximum von-Mises stress at the status of full 
dilation. 
 
 In Fig. 5.11, the maximum circumferential normal stresses are calculated from 
46.5 MPa to 50.16 MPa depending on the strut thicknesses, which means that the stress in 
that direction is dominant among six stress components. The circumferential normal 
stress also increases with strut thickness in linear behavior. 
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Fig. 5.11 Plots of circumferential normal stress on coating component. (a) 
Circumferential normal stress growth with % dilation and (b) Maximum circumferential 
normal stress at the status of full dilation. 
 
 Since most of DES are composed of repeated unit cell design, it is would be 
useful to identify the location of maximum and minimum stress positions along the edge 
of unit cell. Fig. 5.12 displays the line path (purple lines) along the coating edge of stent 
strut in the unit cell, and Fig. 5.13 shows the von-Mises stress profiles from the three 
systems with different thicknesses at the coating edge of strut along the path depicted in 
Fig. 5.12. In Fig. 5.13, the x-axis represents the distance from the starting point of 
analysis. To indicate the maximum and minimum point for convenience, the von-Mises 
stress profile for 80 µm coating thickness was cropped from Fig. 5.13 and re-plotted in 
Fig. 5.15, since the stress profile will show somewhat repeated patterns depending on the 
geometry of the unit cell structure of stent. Due to the periodicity, it is considered that the 
analysis of cropped section shown in Fig. 5.15 can represent the possible variations for 
the entire stent strut. Fig. 5.14 depicts the image to show the starting/ending path and the 
maximum/minimum spots for Fig. 5.15. From these results, as shown in Fig. 5.12, it was 
found that the maximum and minimum points are located at the hinge region of curve and 
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at the middle of strut between two curves, respectively. The maximum von-Mises stress 
location was identified as the near the center of hinge (not the center of the hinge) in the 
inner side of the cell path. In the inner side path, the stress at exact center of hinge is 
predicted to be much smaller than that in the maximum location. The maximum stress 
location along the outer side was also near the center of the hinge, not the exact center 
position. 
 
Fig. 5.12 The path on the edge of model A (SYNERGY stent) strut along the unit cell. 
 
 
Fig. 5.13 The von-Mises stresses variation on the edge of unit cell as a function of 
distance and strut thickness. 
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Fig. 5.14 Cropped path of unit cell structure in model A (SYNERGY stent) from Fig. 
5.12. 
 
 
Fig. 5.15 Cropped von-Mises stress curve for 80 µm. 
 
3. Impacts of Coating Thickness 
 Stresses in the coating component with its thickness variation were also 
investigated for the second set of the study, where the stents were expanded to achieve 
the same level of the dilation by 60 % of the initial diameter. We tested three different 
models with 7µm, 12µm, and 20µm of the coating thicknesses. The strut thickness was 
set as 80 µm as it is regarded as the reference model. 
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 In investigating the stresses in the coating components, it was found that the 
increased strain of the outer surface of the coating component by the accretive coating 
thickness induced higher stress magnitudes. Fig. 5.16 shows the von-Mises stress 
distributions on the coating components of three models with different coating 
thicknesses in the same scale. The maximum von-Mises stresses were 46.50 MPa for 7 
µm coating, 47.4 MPa for 12 µm, and 48.72 MPa for 20 µm, respectively (see Fig. 5.17). 
Although the color differences among three models appear relatively smaller compared 
with those from the simulation with different strut thickness models (see Fig. 5.9), it was 
calculated that the maximum local von-Mises stress in the coating component increases 
by 4.7 % when the coating thickness increases from 7 µm to 20 µm. 
 
 
Fig. 5.16 Contour plots of von-Mises stress on coating component as a function of 
coating thickness. 
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Fig. 5.17 Plots of von-Mises stress on coating component. (a) von-Mises stress growth 
with % dilation and (b) Maximum von-Mises stress at the status of full dilation. 
 
4. Stresses on the arterial wall & plaque 
 Up to this point, we have only discussed stress concentration in the DES medical 
device itself, i.e., stent platform and coating. In this sub-section, we introduce the 
computations containing the biological environment to address the effects of strut 
thickness on the stress distributions in the atherosclerotic plaque and arterial wall. Also, 
results from the recoil phenomena computations are presented. 
 
4.1 Full expansion 
 To evaluate the effects of strut thickness on the stress concentrations on the inner 
surface of an arterial wall, the models with three different strut thicknesses are developed. 
In this set of simulations, the SYNERGY stent system (model A) was also employed. The 
initial inner diameter of the stent was set as 2.29 mm, and the diameter was 3.55 mm 
when the stent is fully expanded, which is 55 % dilation with respect to the initial 
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diameter. As mentioned in the Chapter 4, 55 % of dilation was arbitrary chosen. In this 
section, the stresses at the full expansion in the artery will be considered.  
 Fig. 5.18 shows the von-Mises stress distributions in the arterial wall from the 
three different strut thicknesses when the DES is fully expanded. For direct comparison, 
the same contour scale was used for individual contour maps in Fig. 5.18. Notable is the 
fact that a higher stress over 5.929 MPa is shown in the regions directly contacting to the 
stent. All three stents were expanded by the identical amount as the displacement control 
method was adopted; each model has the same diameter when it is fully expanded. 
Therefore, it can be concluded that the difference of the stresses between these models is 
not derived by the amount of the expansion, but only by the strut thickness. As seen in 
Fig. 5.18, the magnitude of the stress shows a significant increase from 60 µm to 100 µm 
of the thickness. The maximum von-Mises stresses from the model A systems with 60 
µm, 80 µm, and 100 µm strut thicknesses were 6.145, 6.403, and 6.7 MPa, respectively, 
as shown in the bar graph of Fig. 5.19. 
 
 
Fig. 5.18 Von Mises stress in arterial wall with different strut thicknesses. 
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Fig. 5.19 Maximum von Mises stresses on the inner surfaces of arterial walls with 
different strut thicknesses. 
 
Fig. 5.20 illustrates the von-Mises stress profiles on the inner surface of plaque 
wall with three different strut thicknesses. The stress distributions on the plaque surface 
are in particular important because it is known that they are closely related to the fracture 
of endothelium layer and the ISR occurrence rates. From 5.20, it is seen that the 
magnitude of von-Mises stress increases with the strut thickness. However, even the 
overall trend of stress distribution on inner surface of plaque shows similar result from 
that of artery, the location of maximum von-Mises stress is different. The maximum point 
of von-Mises stress in the computational system is located at the upper and/or lower edge 
of plaque. This is because there is higher degree of interactions between stent platform 
and plaque surface at the end of medical devices. However, since the appropriate area to 
represent the stress on the plaque is located on the middle part of its inner surface, a 
selection of a set of elements are required for relevant stress analysis. As given in Fig. 
5.21, we have selected three locations to represent the general stress points of model A. 
With these three locations, the averaged value was used as the value for von-Mises stress 
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on the inner surface of plaque. The averaged von Mises stresses of the 60 µm, 80 µm, and 
100 µm were 2.28, 2.39, and 2.68 MPa, respectively (Fig. 5.22). 
 
 
Fig. 5.20 Von-Mises stress in plaque with different strut thicknesses. 
 
 
Fig. 5.21 Arbitrary selected elements on inner surface of plaque to represent the averaged 
von-Mises stress. 
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Fig. 5.22 Averaged von-Mises stresses on the inner surfaces of plaque with different strut 
thicknesses. 
 
4.2 Recoil Rates 
 When the displacement load exerted on the stent is released to zero (deflation), 
due to the interactions between artery, plaque and stent, the recoil phenomena are 
observed. After the removal of the displacement load, the artery and plaque start re-
narrowing their lumen because of their hyper-elasticity. For this behavior, the stent will 
go through recoil whose magnitude of the rate is determined by the thickness and 
material properties of the stent. In this study, we performed the simulation with three 
models with different strut thicknesses; 60 µm, 80µm, and 100µm. With these variations, 
the recoil rate was calculated by,  
 
܀܍܋ܗܑܔ	ܚ܉ܜ܍ =
ࡰܑܖ܎ܔ܉ܜ܍܌ିࡰ܌܍܎ܔ܉ܜ܍܌
ࡰܑܖ܎ܔ܉ܜ܍܌
	× ૚૙૙%             (5.1) 
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 Where Dinflated is the inner diameter of the stent when the stent is fully expanded 
and Ddeflated is the inner diameter of the stent after the recoil, respectively. Fig. 5.23 shows 
the percentage recoil rate of three stent models with different thicknesses. The recoil rate 
for 60 µm is 18.77 %, 80 µm is 14.93 %, and 100 µm is 6.52 %. From these results, we 
can conclude that the recoil rate of stent strut is highly dependent upon its strut thickness. 
Since the polymer delamination and ISR problems are most likely to occur after a certain 
time, the stress analysis after the recoil should be carried out. 
 
Fig. 5.23 The recoil rates of three stents with different thicknesses. 
 
4.3 Stress distributions after recoil 
 In this section, the von-Mises stresses of each component after recoil will be 
discussed. As mentioned before, it is very important to observe and analyze the stress 
distribution after recoil because this status is closely related to the rate of ISR and/or the 
possibility of polymer coating delamination. In addition, when we modify the thickness 
of strut, the major difference appears after the deflation. Fig. 5.24 depicts the von-Mises 
stress distributions on the inner surfaces of arteries with strut thickness variations, and 
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Fig. 5.25 shows the comparison of maximum von-Mises stresses from the three different 
models. The maximum Mises stresses were 4.171 MPa for 100 µm, whereas 1.027 MPa 
for 60µm, which is 75.4% reduction in magnitude.  
   
 
Fig. 5.24 Von-Mises stresses on the inner surfaces of arterial walls after recoil. 
 
 
Fig. 5.25 Maximum von-Mises stresses on the inner surface of arterial wall after recoil 
with different strut thicknesses. 
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The effect of strut thickness to the von-Mises stress on arterial wall is consistent 
with other FEA studies. In 2009, H. Zahedmanesh and C. Lally [1] performed FEA 
computations for stents with different strut thickness parameters. The authors changed the 
thickness of strut from 50 µm to 140 µm. As seen from Fig. 5.26, the von-Mises stresse 
distributions on arterial wall are obtained with the states of before and after recoil. The 
results produced from the authors show a clear difference from the values of our work 
because the platform materials incorporated in their model is 316L. However, it is 
apparent that the general trend of increasing stress with strut thickness is observed [1].  
 
 
Fig. 5. 26 von-Mises stresses in the arterial wall with thin strut stent (A) and thick strut 
stent (B) [1]. 
 
Fig. 5.27 depicts the von-Mises stress distributions on the inner surfaces of 
plaques with strut thickness variations. From Fig. 5.27, it is apparent that much higher 
stress is concentrated when a thicker stent strut is applied. For more quantitative analysis, 
we show Fig. 5.28 to contain the comparison of averaged von-Mises stresses from the 
three different models. The averaged Mises stresses were 1.428 MPa for 100 µm, 
whereas 0.307 MPa for 60µm, which is 78.4% reduction in magnitude as the strut 
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thickness decreases. Hence, it is thought that the thickness of DES strut is a critical 
parameter to influence the risk of ISR. 
 
Fig. 5.27 Contour map of von-Mises stresses on the inner surface of plaque after recoil 
from model A systems with different strut thicknesses. 
 
 
Fig. 5.28 Averaged von-Mises stresses on the inner surface of plaque after recoil from 
model A with different strut thicknesses. 
 
Fig. 5.29 shows the von-Mises stress distributions in the polymer coating for each 
model after recoil. Similar to the previous results of free expansion, the computation 
shows that the magnitude of Mises stress increases with the strut thickness of stent 
105 
 
 
 
platform at the identical location from previous results. Fig. 5.30 illustrates the 
comparison of maximum Mises stresses with the variation of strut thickness. The 
maximum Mises stresses were 31.91 MPa for 60µm, 33.61MPa for 80µm, and 37.53 
MPa for 100µm, respectively. As the strut thickness increases from 60 µm to 100 µm, the 
maximum Mises stress increases by 14.9 %. 
 
Fig. 5.29 Von-Mises stresses on the polymer coatings after recoil. 
 
 
Fig. 5.30 Maximum von-Mises stresses on the polymer coatings after recoil with 
different strut thicknesses. 
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Fig. 5.31 shows the von-Mises stress difference between before and after recoil on 
the coating components of model A DES. As expected, in all cases, maximum Mises 
stress is considerably decreased after recoil. The percent changes of maximum von-Mises 
stresses on coating in the systems before and after the recoil were 25.1% for 60 µm, 
24.8% for 80 µm and 19.8% for 100 µm, respectively, which shows that, in general, 
higher stress reduction is expected in the system with thin strut after recoil. 
 
Fig. 5.31 Comparison of maximum von-Mises stresses on coating (% change) before and 
after the recoil 
Until now, all the result of Mises stress on the components have increased with 
the thickening the stent strut thickness. However, the last part of result that is evaluating 
the von-Mises stresses on the strut after recoil shows different results. In Fig. 5.32 and 
Fig. 5.33, the contour maps of von-Mises stress distributions and the maximum stresses 
in the stent strut after recoil are respectively shown for the model A systems with 
different strut thicknesses. As we can see from Fig. 5.32 and Fig. 5.33, the general trend 
is different from previous results; the Mises stresses on the strut of 80µm are higher than 
100µm strut. The maximum von-Mises stresses were 623.8 MPa for 60µm, 663.5MPa for 
80 µm, and 645.6 MPa for 100µm, respectively. As we discussed in previous section, the 
plastic behavior and/or the stresses are highly related to the recoil ratio. When 80 µm and 
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100 µm stents are compared, 100 µm stent shows much less recoil ratio than that of 
80µm. Once the fully expanded stent starts to recoil, the stress on the strut begins to be 
alleviated. However, after a certain point, the stress starts regaining its stress because of 
its plastic property. Therefore, it can be explained that the von-Mises stresses on the strut 
with 80µm shows higher magnitude than that of 100µm. Interestingly, the case of 60µm 
does not follow this rule. According to the previous finding, the magnitude of von-Mises 
stress should be the highest among the three models, however, the maximum von-Mises 
stresses for 60µm was 623.8 MPa which is the lowest. Adopting the finding from 
previous section, the magnitude of maximum stress is a function of strut thickness itself. 
Therefore, this result could be explained by that the thickness contribution to its von-
Mises stress is major while the effect of recoil is minor. 
 
Fig. 5.32 Contour map of von-Mises stress distributions on the stent struts after recoil. 
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Fig. 5.33 Maximum von Mises stresses on the polymer after recoil with different strut 
thicknesses. 
 Fig. 5.34 shows the relative changes of maximum von-Mises stresses on the stent 
platform of three systems with different strut thicknesses between before and after recoil. 
60 µm model shows highest difference of 14.75% whereas 100 µm model shows only 
2.2%. It is noteworthy that Mises stress becomes greater after recoil which is opposite to 
that of results for coatings. This phenomenon could be explained by that the residual 
stress is greater than the magnitude of induced Mises stress by full expansion due to high 
stiffness characteristic of Pt-Cr alloy materials. The percent change of maximum von-
Mises stresses between before and after the recoil is 14.75% for 60 µm, 13.9% for 80 µm, 
and 2.2% for 100 µm, respectively. 
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Fig. 5.34 Comparison of maximum von-Mises stresses on stent platform (% change) 
before and after the recoil 
 
The von-Mises stress distribution and the location of maximum point in stent strut 
are observed in similar figuration with other FEA studies. In 2006, Donnelly et al. [2], 
have carried out the research about the stress on stent strut. They adopted commercial 
BMS (Abbott Opencell stent) to predict the von-Mises stress distribution on stent strut 
(see Fig. 5.35). It is thought this work is one of the few reports to contain the stress 
distributions in the stent strut. According to their results, the maximum Mises stresses 
were observed as 580.5 MPa and 540.7 MPa when the stent is fully expanded and 
elastically recoiled, respectively. The maximum Mises stress on strut after recoil is 
decreased since the recoil is occurred within its elastic regime, and the existence with 
contributions of artery and plaque wall was neglected. Even though the direct comparison 
of this result to our work is not feasible due to the dissimilar simulation conditions (i.e., 
material properties, loading conditions), the authors also showed that the location of 
maximum point is the near-link area [2].  
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Fig. 5.35 von-Mises stress distribution on Abbott Opencell stent (BMS) [2]. 
 
Again, it is important to keep track on the locations of maximum and minimum 
Mises stress after recoil. As shown in Fig. 5.36, the regions for the maximum and 
minimum stresses still roughly belong to the near-hinge curve area of inside path and 
middle of strut between curves, respectively, even though the exact locations have been 
somewhat altered. Therefore, it is again expected that there is a higher chance of drug-
polymer coating fracture in this near-hinge area even after the recoil. In Fig. 5.37, the 
von-Mises stress variations are plotted as a function of distance from the pre-defined 
starting point of unit cell structure. The indicators for max/min points shown in Figs. 5.36 
and 5.37 are corresponded to each other. 
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Fig. 5.36 The location of maximum and minimum von-Mises stresses on the coating after 
recoil. 
 
 
Fig. 5.37 The curve of von-Mises stress on the coating along the cropped path after 
recoil. 
5. Stents Comparison: Model A, B, and C 
5.1 Stress distributions in the stent platform 
 Next, we performed FEA simulations to compare the mechanical behaviors of 
three different models, A, B, and C (SYNERGY, TAXUS Express, and FLEX, 
respectively), as introduced in Chapter 4. Fig. 5.38 illustrates the predicted von-Mises 
stresses on stent strut platforms of these three different commercial stents after 60 % of 
dilation from the initial diameters. Unlike the previous results (based only on the model 
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A, SYNERGY stents), unfortunately, they do not share the same scale of legends so that 
the direct comparison is impossible. Each of their simulation conditions is not identical as 
the geometrical parameters and applied material properties are different for these three 
DES products. 316L stainless steel was used for the model B (TAXUS Express2) stent 
and model C (Biomatrix FLEX) stent strut material, whereas Pt-Cr alloy was used for the 
model A (SYNETGY) stent. The SYNERGY stent has PLGA biodegradable coating 
component, TAXUS Express2 has SIBS, and Biomatrix FLEX stent contains PLA 
polymer as drug carrier. As seen in Fig. 5.38, Model B and model C are showing highest 
Mises stresses on the curves whereas model A shows maximum stress location on both 
end sides of curves. Although the direct comparison is not readily available, the contour 
plots shown below implies that it is feasible to predict the regions of high concentrated 
stress where the delamination would be most likely to occur. 
  
 
Fig. 5.38 Contour plots of von-Mises stress distributions on stent strut in three different 
commercial stent products. 
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 Fig. 5.39 shows (a) the von-Mises stress profiles on the stent strut during 
deployment and (b) the maximum Mises stress values for each model. As can be seen 
from this figures, the two stents (model A and model C), the newer commercial products, 
show considerably less von-Mises stress concentrations compared to the model B which 
is 1st generation of DES. At the early stage of deployment, Model A shows much higher 
stress than other models, but the stress of Model C continuously increases and becomes 
greater than Model A after the yield point (see Fig. 5.39(a)) due to the material property 
of 316L stainless steels. Although the materials used for each models are different, the 
general tendency of newer generation stents show much less than that of earlier 
generation stent. The result shows that the Model A exhibits the lowest maximum stress 
of 607.2 MPa, whereas the Model B shows the highest maximum stress of 706.4 MPa 
(see Fig 5.39(b)). 
  
 
Fig. 5.39 Plots of (a) von-Mises stress profiles on the stent strut as a function of % 
dilation and (b) the maximum Mises stress from three different types of DES products. 
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5.2 Stress distributions in the coating 
 The last set of computation in this work includes evaluating the von-Mises 
stresses on the coating components in the three commercial DES. Fig. 5.40 illustrates the 
contour plots of von-Mises stress distributions on coatings for each model. The 
magnitude difference of maximum stress is glaringly obvious in coating comparison, as 
shown in Fig. 5.40; the Model B shows very low and locally concentrated Mises stress 
compared with other models.  
 
Fig. 5.40 Contour plots of von-Mises stress distributions on coating components in three 
different commercial stent products. 
 
 Fig. 5.41 illustrates the maximum von-Mises stresses on the coating components 
of the three model systems. Since the SIBS, the drug carrier polymer for model B, has 
almost elastomer material properties such as very low modulus and yield strength, the 
maximum Mises stress is 0.5334 MPa which is almost negligible. The highest maximum 
stress is 63.88 MPa which is monitored in model B, whereas model A shows 46.53 MPa. 
To predict and investigate the coating delamination of coating, another approach 
could be utilized as well as observation of von-Mises stress. As mentioned in previous 
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section, Hopkins et al. [3], performed the FEA simulations to reveal the coating 
delamination phenomena. The authors adopted cohesive zone model as the governing 
equation for describing this behavior. From their result, the critical bonding strength that 
can initiate the delamination of coating (SIBS coating) is calculated as 0.009 MPa, 
whereas our study predicts 0.5334 MPa for the coating fracture and/or fragmentation. The 
stent system is comprised of stainless steels with three different types of drug-polymer 
coatings. The majority factor to differentiate these two studies would be the different 
degrees of dilation. The study from Hopkins measures the bonding strength at the status 
of initiation of delamination whereas this thesis observes the maximum stress at the status 
of fully expanded status. In the present state, prediction of coating delamination at 
specific point of dilation is unfeasible since the observed stress on the coating component 
in this study is based on von-Mises stress. Therefore, again, it is not currently possible to 
directly compare these two sets of results because the computational systems and the 
analysis approaches are clearly different. Currently, the prediction of coating 
delamination related to the shear stress analysis will be implemented in the future work as 
will be mentioned in the next chapter.  
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(a)                                                          (b) 
 
Fig. 5.41 Plots of (a) von-Mises stress profiles on the coating as a function of % dilation 
and (b) the maximum Mises stress from three different types of DES products. 
 
 To identify the locations of maximum and minimum stress locations for models B 
and C, same method using the unit cell analysis has been adopted. Figs. 5.42 to 5.45 
show the locations of maximum and minimum von-Mises stress concentrations for model 
B and C, respectively. For both of the model B and C systems (TAXUS Express and 
FLEX products, respectively), it was found that the maximum stress points are located at 
the center position of hinge area, which is clearly different from the case of model A 
(near-hinge area). In addition, the maximum stress location in model B was identified in 
the position of the outer path of smaller ring (the stent platform of model B is composed 
of two sizes of ring structures, i.e., small and large rings), while the maximum stress was 
observed in the position of inner path of the unit cell structure.  
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Fig. 5.42 The location of maximum von-Mises stress on the coating component of model 
B. 
 
 
Fig. 5.43 The curve of von-Mises stress on the coating component of model B along the 
cropped path of the unit cell structure analysis. 
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Fig. 5.44 The location of maximum von-Mises stress on the coating component of model 
C. 
 
 
Fig. 5.45 The curve of von-Mises stress on the coating component of model C along the 
cropped path of the unit cell structure analysis. 
 
 As a final remark, it is considered that the validation of the generated 
computational results is necessary. However, experimental measurements for the 
mechanical behaviors from these small DES medical devices are not trivial tasks. For 
now, the simulation results of maximum stress locations show qualitatively consistent 
prediction to the experimental coating fracture phenomenon as shown in Chapter 1. The 
FEA model developed through the current study is thought to be readily applied to 
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predict the mechanical responses of DES systems including thin coating components. 
Further, it is anticipated that this work can be used as a basis to guide the optimized DES 
designs including the geometry and material factors. In the future, it is planned to extend 
the present research to incorporate much advanced computational analysis techniques and 
theories.  
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Chapter 6. Summary 
 
Advanced computational numerical methods have emerged as essential tools for 
the assessment and optimization of the performance of biomedical devices such as 
coronary stent products. In the present thesis, we employed the finite element analysis 
(FEA) computation technique to predict the mechanical behavior of drug-eluting stents 
(DES) medical devices that are interfaced with drug-polymer coatings. To date, FEA has 
been widely utilized in a large number of studies of DES products to investigate the 
mechanical properties and their biomechanical impact on the diseased coronary artery 
during deployment. Over the past decade, rapid improvement of computational power has 
led to a considerable improvement in the level of complexity and sophistication involved 
in these studies. Today, elaborate models of commercially available stents, tri-folded 
catheter balloons, and stenotic arteries are regarded as the norm, despite the idealized or 
simplified material properties are often used to describe the behavior of complicated 
biological tissues. However, the contemporary research trend also includes the 
development of sophisticated hyper-elastic constitutive material models that can replace 
the previous simplified approximations. 
In this study, unlike the previous investigations focusing on bare metal stents 
(BMS), we have considered the comprehensive DES system that incorporates the drug-
polymer coating in the FEA model. FEA model has been developed to reliably predict the 
stress distributions in the various components of DES system. The developed FEA model 
allows to evaluate and compare the impacts of material/geometrical parameters. Our 
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models also include the examination of the stress distributions in the biological 
environment, i.e., atherosclerotic plaque and arterial wall. 
Validation work has been initially carried out to verify that 2D and 3D coating 
elements produce consistent results. Then, using 2D coating elements, the influences of 
strut thicknesses and coating thicknesses on the von-Mises stress concentrations in the 
coating were examined. From the results, it has been observed that the strut thickness and 
coating thickness of stent are one of the dominant factors to determine its mechanical 
performance. DES system with thicker strut exhibited much higher von-Mises stress 
accumulation than thinner strut. And, it was also predicted that the stress on coating 
component increases as the coating thickness increases. Incorporation of the arterial wall 
and atherosclerotic plaque components in the computational system enables to investigate 
the stresses on the inner surface of arterial wall that can be utilized to understand the rate 
of in-stent restenosis (ISR). In our study, it has been found that the strut thickness plays a 
very important role in determining the degree of recoil phenomenon. Through a series of 
FEA computations, we showed that the recoil rate increases and the stress on the arterial 
wall decreases by adopting thinner struts in noticeable amounts. In addition, the regions 
with maximum and minimum von-Mises stress were identified, and the circumferential 
normal stress is turned out to be the major contributor to the stress concentrations out of 
the 2D three stress components. 
Finally, it is considered that the development of a more complicated model would 
be necessary to quantitatively examine the fracture mechanisms of DES coatings with 
various geometry/material designs. Toward this, developing models containing multi-
layered 3D elements for coating components is required to evaluate the shear stress 
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components in the coating/stent platform interface areas. Further, an advanced fracture 
theory such as cohesive zone model can be included in the computational analysis. 
However, all of these efforts will require a comprehensive 3D analysis that significantly 
limits the size of the computational domain even with the modern computational 
techniques and resources. Development of such advanced model remains as a future work 
with considerable challenges.  
1. Limitations 
 
 Evaluating shear stresses was unable to be performed since using 2D elements. 
 Material properties for drug-polymer component are assumed to be pure polymer 
and homogeneous. 
 Consideration of transient behavior of stent deployment was neglected. 
 
2. Findings 
 
 FEA model to predict the stress distributions in the various components including 
drug-polymer coating in DES medical devices has been developed. 
 2D and 3D coating elements showed almost identical results in von-Mises stress. 
 Maximum local von-Mises stress in the stent strut increases by 8.5 % when the 
strut thickness increases from 60 µm to 100 µm. 
 Maximum local von-Mises stress in the coating component increases by 4.7 % 
when the coating thickness increases from 7 µm to 20 µm. 
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 Normal stress along the stent circumferential direction shows the highest 
distribution. 
 Incorporation of the arterial wall and atherosclerotic plaque compounds in the 
computational system enables to investigate the stresses on the inner surface of 
arterial wall that can be utilized to understand the rate of ISR. 
 The recoil rate increases and the stress on the arterial wall decreases by adopting 
thinner struts in noticeable amounts. 
 The regions with maximum and minimum von-Mises stresses in coating 
components for each model were identified. 
 Adhesion strength between the coating and the strut platform must be greater than  
o 50~55 MPa for the SYNERGY system 
o 0.6~1.0 MPa for the TAXUS Express2 system 
o 65~70 MPa for the Biomatrix FLEX system 
considered in the current work to avoid the coating delamination upon 
implantation. 
 
3. Future works 
 
 Developing models containing multi-layered 3D elements for coating component 
is required to investigate shear stresses. 
 Refinement of model will require including more accurate material properties (i.e., 
existence of drug phases). 
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 Pressure control with explicit method needs to be adopted to evaluate transient 
behavior of stent in future work. 
 Propose optimum DES with advanced materials and geometric design. 
